Anti-FGFR3 antibodies and uses thereof
By developing a new anti-FGFR3 antibody, using specific amino acid sequences and biopanning technology, the problem of insufficient targeted degradation rate and efficacy of existing antibodies in FGFR3-TACC3 overexpressing cells is solved, and higher binding power is achieved and therapeutic effects.
Patent Information
- Application Number
- CN202111647441.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-01-05
- Filing Date
- 2021-12-29
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-12-29
AI Technical Summary
Existing anti-FGFR3 antibodies have shortcomings in targeted degradation rates and efficacy, especially in poor therapeutic effects on FGFR3-TACC3 overexpressing brain tumor cells.
A novel anti-FGFR3 antibody has been developed that contains specific heavy and light chain variable region amino acid sequences, which has higher affinity and targeted degradation rates compared to well-known antibodies, combined with biopanning and recombinant expression Technology prepares to form bispecific antibodies or chimeric antigen receptors for targeting cancer cells overexpressed by FGFR3-TACC3.
The novel anti-FGFR3 antibody significantly improves the binding force of FGFR3 and inhibits cancer cell growth, especially the therapeutic potential in FGFR3-TACC3 overexpressing brain tumor cells, showing better efficacy.
Smart Images

Figure CN114716548B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an anti-fibroblast growth factor receptor 3 (FGFR3) antibody or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a recombinant expression vector comprising the nucleic acid, a host cell transfected by the recombinant expression vector, a method for preparing the antibody or the antigen-binding fragment thereof, a bispecific antibody or a multispecific antibody comprising the antibody or the antigen-binding fragment thereof, an scFv comprising the antibody and an scFv comprising one or more second binding domains of the scFv of the antibody that binds to an immune cell activation antigen, and an immune cell binding protein (immune cell binding protein) comprising the antibody. The invention relates to a bispecific antibody or a multispecific antibody that binds to a target gene or antigen-binding fragment thereof, an antibody-drug conjugate (ADC) in which the antibody or its antigen fragment is bound to a drug, a chimeric antigen receptor (CAR) comprising the scFv of the anti-FGFR3 antibody as an antigen-binding site of the extracellular domain, an immune cell introduced with the chimeric antigen receptor, a combination therapy composition comprising the immune cell, a combination therapy composition comprising the antibody or its antigen-binding fragment, a composition for treating cancer, inflammation or immune disease, a method for treating cancer, inflammation or immune disease, and a vesicle comprising the antibody or its antigen-binding fragment. Background Art
[0002] Fibroblast growth factor (FGF) and its tyrosine kinase receptor (FGFR) play an important role in embryogenesis, homeostasis of various tissues, wound healing process and metabolic function. In humans, there are FGFRs (FGFR1-4) and 22 FGFs (FGF1-14 and FGF16-23) with high homology. FGFR contains: an extracellular region containing D1, D2 and D3 as three immune domains, a single transmembrane domain and a split cytoplasmic kinase part.
[0003] Dysregulation of signaling caused by FGFR1-4 is associated with the etiology of various cancers. Due to variations in genomic FGFRs, including gene amplification, chromosomal translocation, and activating mutations, abnormal activation of the FGF pathway and tumor transformation of normal cells are promoted. In particular, amplification of FGFR3 is known to be associated with the induction of bladder cancer. In particular, missense FGFR variations are observed in various types of cancer, and due to S249C of FGFR3, FGF-driven signaling and tumor cell proliferation may be enhanced, and it shows a hotspot for somatic mutations.
[0004] In the past, cancer therapeutic agents were developed by focusing on targeting this FGF / FGFR pathway. In addition, in recent years, fusion proteins caused by chromosome rearrangement as oncogenic mutations have been found in glioblastoma, lung cancer, bladder cancer, oral cancer, head and neck squamous cell carcinoma, gallbladder cancer, or cervical cancer. This fusion protein is formed by the fusion of the FGFR3 gene and the transforming acidic coiled-coil containing protein 3 (TACC3) gene due to the tandem duplication of chromosome 4. Since the FGFR monomers in the fusion protein are close enough to the dimerizing domain of the partner protein that can be activated, FGFR can be continuously activated. In FGFR3-TACC3, due to the coiled-coil domain of TACC3, FGFR3 is autophosphorylated and activated without ligand binding.
[0005] TACC3 belongs to the TACC family, and rearrangement in chromosome 4p16 corresponding to the region containing TACC3 and FGFR3 is often confirmed in multiple myeloma, which leads to increased expression of FGFR3 or TACC3 (KN Nelson et al., Oncotarget. 2018 Sep 28; 9(76): 34306-34319).
[0006] Based on the above-mentioned findings, clinical trials of antibodies targeting FGFR3 or fusion genes with the FGFR3 gene have been conducted in recent years.
[0007] B701 (Vofatamab) is a human immunoglobulin G1 monoclonal antibody to FGFR3, and clinical trials are conducted to confirm whether it shows anti-tumor activity and the possibility of combining with docetaxel. When the anti-FGFR3 monoclonal antibody B-701 is used, it specifically binds to and inhibits both the wild type and mutation of FGFR3, inhibits the activation of FGFR3 and the signal transduction pathway mediated by FGFR3 by inhibiting the phosphorylation of FGFR3. Thus, cell proliferation is inhibited, and cell death is induced in FGFR3-expressing tumors.
[0008] LY3076226 is an antibody-drug conjugate (ADC) of an anti-FGFR3 antibody and DM4 (microtubule inhibitor), and a phase I clinical trial was conducted to confirm whether LY3076226 is effective for advanced or metastatic cancer, including multiple myeloma and lymphoma, with overexpression or modification of FGFR3, and locally advanced, unresectable or metastatic urinary tract cancer (T Ibrahim et al., Bladder Cancer, vol.5, no.2, pp.87-102, 2019).
[0009] Such existing anti-FGFR3 antibodies exhibit low affinity, targeted degradation rate, and efficacy. As a result of intensive efforts to develop novel anti-FGFR3 antibodies having improved affinity, targeted degradation rate, and efficacy compared to existing anti-FGFR3 antibodies, the present inventors have confirmed antibody properties such as affinity, FGFR3 binding pattern analysis, FGFR3 degradation rate confirmation, cancer cell growth inhibition results, and efficacy test results. In particular, they have screened antibodies with differentiated properties by a strategy of screening for antibodies that have a more sensitive reactivity to cells derived from FGFR3-TACC3-overexpressing brain tumor patients than known anti-FGFR3 antibodies, and have confirmed that the screened antibodies can be used for desired cancer treatment, thereby completing the present invention. Summary of the invention
[0010] Technical issues to be solved
[0011] The object of the present invention is to provide a novel antibody or an antigen-binding fragment thereof targeting fibroblast growth factor receptor 3 (FGFR3).
[0012] In particular, the present invention aims to screen for antibodies that have more sensitive reactivity to cells derived from FGFR3-TACC3-overexpressing brain tumor patients than known anti-FGFR3 antibodies.
[0013] Another object of the present invention is to provide a nucleic acid encoding the antibody or antigen-binding fragment thereof.
[0014] Another object of the present invention is to provide a host cell, which is transfected with a recombinant expression vector comprising the nucleic acid or the recombinant expression vector.
[0015] Another object of the present invention is to provide a method for preparing an antibody or an antigen-binding fragment thereof that specifically binds to FGFR3.
[0016] Another object of the present invention is to provide a bispecific antibody or multispecific antibody comprising the antibody or antigen-binding fragment thereof.
[0017] Another object of the present invention is to provide an immune cell engaging bispecific antibody or multispecific antibody comprising the antibody or antigen-binding fragment thereof.
[0018] Another object of the present invention is to provide an antibody-drug conjugate (ADC) in which the antibody or antigen-binding fragment thereof is combined with a drug.
[0019] Another object of the present invention is to provide a combination therapy composition comprising: a chimeric antigen receptor (CAR), an immune cell introduced with the chimeric antigen receptor, and the immune cell, wherein the chimeric antigen receptor comprises the scFv of the anti-FGFR3 antibody as an antigen binding site of the extracellular domain.
[0020] Another object of the present invention is to provide a combination therapy composition comprising the antibody or antigen-binding fragment thereof or the immune cell-engaging bispecific antibody or multispecific antibody.
[0021] Another object of the present invention is to provide a composition for treating cancer or a method for treating cancer, the composition comprising: an antibody or an antigen-binding fragment thereof, a bispecific antibody or a multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate comprising the antibody or its antigen-binding fragment, a chimeric antigen receptor comprising the antibody or its antigen-binding fragment, and the chimeric antigen receptor.
[0022] Another object of the present invention is to provide a vesicle comprising the antibody or antigen-binding fragment thereof.
[0023] Technical Solution
[0024] In order to achieve the above-mentioned object, the present invention provides an antibody or an antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising: a heavy chain CDR1 comprising one or more amino acid sequences selected from SEQ ID NO.1 to SEQ ID NO.18; a heavy chain CDR2 comprising one or more amino acid sequences selected from SEQ ID NO.19 to SEQ ID NO.41; a heavy chain CDR3 comprising one or more amino acid sequences selected from SEQ ID NO.42 to SEQ ID NO.66, SEQ ID NO.186 to SEQ ID NO.198; a light chain CDR1 comprising one or more amino acid sequences selected from SEQ ID NO.67 to SEQ ID NO.88; a light chain CDR2 comprising one or more amino acid sequences selected from SEQ ID NO.89 to SEQ ID NO.109; and a light chain CDR3 comprising one or more amino acid sequences selected from SEQ ID NO.110 to SEQ ID NO.132, SEQ ID NO.199 to SEQ ID NO.202.
[0025] The present invention provides a nucleic acid encoding the antibody or the antigen-binding fragment thereof.
[0026] The present invention also provides a recombinant expression vector comprising the nucleic acid.
[0027] The present invention also provides a host cell, which is transfected by the recombinant expression vector.
[0028] The present invention also provides a method for preparing an antibody or an antigen-binding fragment thereof that specifically binds to FGFR3, which comprises the following steps: culturing host cells to form antibodies; and separating and purifying the formed antibodies.
[0029] The present invention also provides a bispecific antibody or multispecific antibody comprising the antibody or the antigen-binding fragment thereof.
[0030] The present invention also provides an immune cell engaging bispecific antibody or multispecific antibody, which comprises an scFv of the antibody and an scFv consisting of a second binding domain, wherein the second binding domain comprises one or more scFvs of antibodies that bind to an immune cell activating antigen.
[0031] The present invention also provides an antibody-drug conjugate (ADC) in which the antibody or antigen-binding fragment thereof is combined with a drug.
[0032] The present invention also provides a chimeric antigen receptor, characterized in that the chimeric antigen receptor (CAR) comprises: an extracellular domain comprising an antigen binding site, a transmembrane domain and an intracellular signaling domain, and the antigen binding site of the extracellular domain is the scFv of the antibody.
[0033] The present invention also provides an immune cell comprising the chimeric antigen receptor (CAR).
[0034] The present invention also provides a combination therapy composition comprising the immune cell and a drug other than the anti-FGFR3 antibody.
[0035] The present invention also provides a combination therapy composition comprising the antibody or its antigen-binding fragment, and one or more selected from (i) immune cells; (ii) immune cells comprising an antigen receptor (CAR), wherein the antigen receptor comprises an scFv fragment of an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) an immune checkpoint inhibitor.
[0036] The present invention also provides a combination therapy composition comprising the bispecific antibody or multispecific antibody, and one or more selected from (i) immune cells; (ii) immune cells comprising an antigen receptor (CAR), wherein the antigen receptor comprises an scFv fragment for an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) an immune checkpoint inhibitor.
[0037] The present invention also provides a composition for treating cancer, comprising: the antibody or its antigen-binding fragment, a bispecific antibody or a multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate comprising the antibody or its antigen-binding fragment, a chimeric antigen receptor comprising the antibody or its antigen-binding fragment, or an immune cell introduced with the chimeric antigen receptor.
[0038] The present invention also provides a composition for treating cancer, which is used to treat cancer confirmed to be amplified, mutated, overexpressed or always expressed (constitutive activation) of the fusion gene of FGFR3 and TACC3, and comprises: the antibody or its antigen-binding fragment, a bispecific antibody or multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate comprising the antibody or its antigen-binding fragment, a chimeric antigen receptor comprising the antibody or its antigen-binding fragment, or an immune cell introduced with the chimeric antigen receptor.
[0039] The present invention also provides a method for treating cancer, comprising the following steps: confirming in a sample derived from a patient that a fusion gene of FGFR3 and TACC3 is amplified, a fusion gene is mutated, a fusion gene is overexpressed, or a fusion gene is always expressed (constitutive activation); and administering the antibody or its antigen-binding fragment, a bispecific antibody or a multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate comprising the antibody or its antigen-binding fragment, a chimeric antigen receptor comprising the antibody or its antigen-binding fragment, or an immune cell into which the chimeric antigen receptor is introduced, when amplification, mutation, overexpression, or constant expression of the fusion gene of FGFR3 and TACC3 is confirmed.
[0040] The present invention also provides a vesicle, wherein the antibody or the antigen-binding fragment thereof is exposed on the outside of the vesicle or exists inside the vesicle.
[0041] Beneficial Effects
[0042] The anti-FGFR3 antibodies or antigen-binding fragments thereof of the present invention show superior binding ability to FGFR3 compared to existing anti-FGFR3 antibodies, and can be usefully used for the prevention or treatment of desired tumors or cancers.
[0043] In particular, by screening cells derived from patients with FGFR3-TACC3-overexpressing brain tumors, antibodies were screened that have superior efficacy against FGFR3-TACC3-overexpressing cancer cells compared to known anti-FGFR3 antibodies. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] FIG. 1 shows a schematic diagram of biopanning based on phage display used in the present invention. Figure 1a A schematic diagram showing cell panning using cells derived from patients overexpressing FGFR3, Figure 1b is a schematic diagram showing solid phase biopanning using FGFR3 recombinant protein, Figure 1c This is a schematic diagram of liquid phase biopanning using FGFR3 recombinant protein. Figure 1d Schematic diagram of magnetic-based semi-automated panning using FGFR3 recombinant protein.
[0045] Figure 2a The biopanning results for antibody screening of the present invention are shown.
[0046] Figure 2b The ELISA screening results for antibody screening of the present invention are shown.
[0047] Figure 2cThe results of magnetic beads based panning for antibody screening of the present invention are shown.
[0048] Figure 3a Schematic diagram showing the conversion from scFv to IgG format.
[0049] Figure 3b Shown are the results of Expi293-based antibody production and purity / physical property analysis.
[0050] Figures 4a to 4d The results of affinity ELISA of FGFR3 antibody (IgG) are shown. Figure 4a The specific binding ability of the antibody against the recombinant protein human FGFR3-IIIc is shown. Figure 4b The specific binding ability of the antibody against the recombinant protein human FGFR3-IIIb is shown. Figure 4c The specific binding ability of the antibody against the recombinant protein mouse FGFR3d is shown. Figure 4d The specific binding ability of the antibody against the recombinant protein cynomolgus monkey FGFR3 is shown.
[0051] Figure 5 The KD value evaluation results of FGFR3 antibody (IgG) using the biomacromolecule interaction analysis system (Biacore) 3000 are shown.
[0052] FIG. 6 shows the confirmation of FGFR3 expression in brain tumor patient-derived cells and the results of FGFR3-TACC3 fusion analysis. Figure 6a The results of mRNA expression level (RPKM) analysis, protein expression level analysis (Western blotting), and cell surface expression analysis (FACS analysis) of patient-derived cells are shown. Figure 6b The figure shows whether FGFR3-TACC3 is fused by RT-PCR: fusion specific primer.
[0053] Figure 7a Shown are the results of cell surface binding analysis of FGFR3 antibody clones derived from FGFR3 (-TACC3) overexpressing brain tumor patient cells. Figure 7b The results of analyzing the binding patterns of the F309 antibody at various concentrations to cells derived from brain tumor patients overexpressing FGFR3 (-TACC3) are shown. Figure 7cThe results of the binding analysis of F309 and FS306 antibodies to cell lines that do not express FGFR3 are shown.
[0054] Figure 8 The figure shows the results of FACS-based analysis and screening of the degradation rate of FGFR3 antibodies on the surface of patient-derived cells (-TACC3).
[0055] Figure 9a The results of analysis of the FGFR3-specific binding ability of the F309 and FS306 antibodies and confirmation of their ligand non-competitive properties are shown. Figure 9b The results of the intrinsic epitope domain recognition of F309 and FS306 antibodies: Domain I are shown. Fig.9c Shown are the results of recombinant domain design for epitope domain mapping.
[0056] FIG. 10 shows the results of the targeted degradation rate analysis of F309 and FS306 antibodies on cells derived from FGFR3-TACC3 overexpressing brain tumor patients and FGFR3 overexpressing cell lines. Fig.10a The results of FACS analysis are shown for cell surface FGFR3-TACC3 and FGFR3 degradation rate analysis using F309 and FS306 antibodies. Fig.10b Shown are the results of Western blotting of total FGFR3-TACC3 and FGFR3 degradation rate analysis of F309 and FS306 antibodies.
[0057] FIG. 11 shows the results of cellular internalization analysis of F309 and FS306 antibodies. Fig.11a Shown are the results of ICC analysis of cellular internalization in cells derived from FGFR3-TACC3 overexpressing brain tumor patients. Fig.11b The results of confirming the lysosomal degradation mechanism of F309 and FS306 antibodies by treatment with a lysosome inhibitor are shown.
[0058] Fig.12 The results of FGFR3 sub-signaling inhibition analysis of F309 and FS306 antibodies are shown.
[0059] Fig.13a The results of ligand-dependent cell growth inhibition analysis (FGF1, FGF9) are shown. Fig.13b The results of ligand-independent cell growth inhibition analysis (derived from FGFR3-TACC3 overexpressing brain tumor patient cells, FGFR3 low-expressing cell lines or derived from brain tumor patient cells) are shown.
[0060] Fig.14aThe results of short-term PK analysis of F309 and FS306 are shown. Fig.14b Shown are the results of antibody efficacy evaluation in FGFR3-TACC3-overexpressing brain tumor patient-derived cell-transplanted mice (PDX). Fig.14c The results of the efficacy evaluation of F309 antibody in PDX models (derived from FGFR3-TACC3 overexpressing brain tumor patient cells) are shown.
[0061] Fig.15a Shown are the 3D and 2D structures of the F309 antibody and a schematic diagram of the strategic affinity enhancement. Fig.15b The results of affinity comparison of F309 affinity-improved antibodies by affinity ELISA are shown. Fig.15c The results of SPR analysis of F309 affinity-improved antibodies are shown. Fig.15d The results of ligand-independent cell growth inhibition analysis of F309 improved antibody clones (derived from FGFR3-TACC3 overexpressing brain tumor patient cells) are shown.
[0062] Fig.16a A schematic diagram showing the preparation of an antibody-drug conjugate (ADC) for confirming the applicability of the F309 antibody. Fig.16b The results of cytotoxicity analysis of F309-vc MMAE on cells derived from FGFR3-TACC3 overexpressing brain tumor patients and FGFR3 overexpressing cell lines are shown. Fig.16c The results of cytotoxicity analysis-1 according to the FGFR3 expression level of F309-vc MMAE are shown. Fig.16d The results of cytotoxicity analysis-2 according to the FGFR3 expression level of F309-vc MMAE are shown.
[0063] Fig.17 The Fv structure and epitope domain mapping of the affinity matured antibodies and the results of antigen-specific binding analysis are shown.
[0064] Fig.18 The results of analysis of the extent of cell surface antigen expression in cells and cell lines derived from FGFR3-TACC3 brain tumor patient cells are shown.
[0065] Fig.19 Shown are the results of analyzing the cellular internalization efficiency of affinity matured antibodies.
[0066] Fig. 20 The results of FGFR3 (-TACC3) targeted degradation rate analysis of affinity matured antibodies are shown.
[0067] Fig.21 Shown are the results of mouse PK analysis of affinity matured antibodies.
[0068] Fig. 22 Shown are the results of monkey PK analysis of affinity matured antibodies.
[0069] Fig.23 Schematic diagram of ADC preparation comprising affinity matured antibodies (Topoisomerase I inhibitor conjugated).
[0070] Fig.24 Schematic diagram of ADC preparation comprising affinity matured antibodies (topoisomerase I inhibitor conjugation) is shown.
[0071] Fig.25 Shown are the results of physical properties and binding capacity analysis of ADCs comprising affinity matured antibodies.
[0072] Fig.26 Shown are the results of physical property analysis of ADCs comprising affinity matured antibodies.
[0073] Fig. 27 Shown are the results of in vitro efficacy evaluation of ADCs comprising affinity matured antibodies.
[0074] Fig.28 Shown are the results of in vitro efficacy evaluation of ADCs comprising affinity matured antibodies.
[0075] Fig.29 Shown are the results of in vivo efficacy evaluation of ADCs comprising affinity matured antibodies.
[0076] Fig.30 Shown are the results of in vivo efficacy evaluation of ADCs comprising affinity matured antibodies.
[0077] Fig.31 Shown are the results of in vivo efficacy evaluation of ADCs comprising affinity matured antibodies.
[0078] Fig.32 Shown are the results of ADC efficacy evaluation of ADCs comprising affinity matured antibodies in a FGFR3 (fused to TACC3) brain tumor stereotactic animal model. DETAILED DESCRIPTION
[0079] Unless otherwise defined, all technical terms and scientific terms used in this specification have the same meaning as those commonly understood by those skilled in the art of the invention. Generally, the nomenclature used in this specification is the nomenclature well known and commonly used in the art.
[0080] Anti-FGFR3 Antibodies
[0081] One aspect of the present invention relates to an antibody or an antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), comprising: a heavy chain CDR1 comprising one or more amino acid sequences selected from SEQ ID NO.1 to SEQ ID NO.18; a heavy chain CDR2 comprising one or more amino acid sequences selected from SEQ ID NO.19 to SEQ ID NO.41; a heavy chain CDR3 comprising one or more amino acid sequences selected from SEQ ID NO.42 to SEQ ID NO.66, SEQ ID NO.186 to SEQ ID NO.198; a light chain CDR1 comprising one or more amino acid sequences selected from SEQ ID NO.67 to SEQ ID NO.88; a light chain CDR2 comprising one or more amino acid sequences selected from SEQ ID NO.89 to SEQ ID NO.109; and a light chain CDR3 comprising one or more amino acid sequences selected from SEQ ID NO.110 to SEQ ID NO.132, SEQ ID NO.199 to SEQ ID NO.202.
[0082] The term "antibody" used in this specification refers to an anti-FGFR3 antibody that specifically binds to FGFR3. In the scope of the present invention, the antibody not only includes a complete antibody form that specifically binds to FGFR3, but also includes an antigen-binding fragment of the antibody molecule. Depending on the circumstances, the antibody of the present invention can target FGFR3-TACC3. In particular, compared with known anti-FGFR3 antibodies, the antibody of the present invention is screened as an antibody that has a more excellent effect on cancer cells that overexpress FGFR3-TACC3.
[0083] A complete antibody has a structure of two full-length light chains and two full-length heavy chains, with each light chain linked to a heavy chain by disulfide bonds.
[0084] The term "heavy chain" used in this specification refers to a full-length heavy chain and a fragment thereof comprising a variable region domain VH and CH1, CH2 and CH3 as three constant region domains, wherein the variable region domain VH comprises an amino acid sequence having a sufficient variable region sequence for imparting specificity to an antigen. In addition, the term "light chain" used in this specification refers to a full-length light chain and a fragment thereof comprising a variable region domain VL and a constant region domain CL, wherein the variable region domain VL comprises an amino acid sequence having a sufficient variable region sequence for imparting specificity to an antigen.
[0085] The whole antibody includes subtypes of IgA, IgD, IgE, IgM and IgG, and in particular, IgG includes IgG1, IgG2, IgG3 and IgG4. The heavy chain constant region has γ, μ, α, δ and ε types, and has γ1, γ2, γ3, γ4, α1 and α2 as subtypes. The constant region of the light chain has κ and λ types.
[0086] The antigen-binding fragment of an antibody or antibody fragment refers to a fragment having an antigen-binding function, and includes Fab, F(ab′), F(ab′)2, and Fv, etc. Among antibody fragments, Fab is a structure having variable regions of light and heavy chains, a constant region of a light chain, and a first constant region (CH1) of a heavy chain, and has one antigen-binding site. The difference between Fab′ and Fab is that the Fab′ has a hinge region that contains one or more cysteine residues at the C-terminus of the heavy chain CH1 domain. F(ab′)2 is formed when the cysteine residues in the hinge region of Fab′ form a disulfide bond.
[0087] Fv corresponds to the smallest antibody fragment having only the heavy chain variable region and the light chain variable region. Double-chain Fv (two-chain Fv) is a heavy chain variable region and a light chain variable region connected by non-covalent bonds, and single-chain Fv (single-chain Fv, scFv) is a heavy chain variable region and a light chain variable region connected by covalent bonds or directly connected at the C-terminus, generally through a peptide linker, so that it can form a structure such as a dimer like a double-chain Fv. This antibody fragment can be prepared by using proteolytic enzymes (for example, when the intact antibody is restrictedly cleaved with papain, Fab can be obtained, and when it is cleaved with pepsin, F(ab′)2 can be obtained) or genetic recombination technology.
[0088] An "Fv" fragment is an antibody fragment that contains the complete antibody recognition and binding site. This region is a dimer of one heavy chain variable domain and one light chain variable domain.
[0089] The "Fab" fragment contains the variable and constant domains of the light chain, the variable domain and the first constant domain (CH1) of the heavy chain. The F(ab')2 antibody fragment generally contains a pair of Fab' fragments covalently linked by cysteine present in the hinge region at the C-terminus of the Fab' fragment.
[0090] "Single-chain Fv (scFv)" antibody fragment is a structure formed by a single polypeptide chain comprising the VH and VL domains of an antibody. ScFv may further comprise a polypeptide linker between the VH and VL domains so that a desired structure can be formed to bind to an antigen.
[0091] In one embodiment, the antibodies of the present invention include monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, scFv, Fab fragments, F(ab′)2 fragments, disulfide-linked Fvs (sdFv) and anti-idiotypic (anti-Id) antibodies or epitope-binding fragments of the antibodies, etc., but are not limited thereto.
[0092] The heavy chain constant region may be selected from any one of the isotypes of γ, μ, α, δ or ε. For example, the constant region is IgG1, IgG2, IgG3 or IgG4. The light chain constant region may be of the κ or λ type.
[0093] The monoclonal antibody refers to an antibody substantially obtained from a homogeneous antibody group, that is, except for a possible spontaneous mutation that may exist in trace amounts, each antibody occupying the group is the same antibody. Monoclonal antibodies have a high degree of specificity and are therefore induced against a single antigenic site. Typically, each monoclonal antibody is directed against a single determinant on the antigen, compared to the usual (polyclonal) antibodies comprising different antibodies directed against different determinants (epitopes).
[0094] "Epitope" refers to a protein determinant to which an antibody can specifically bind. Epitopes are usually composed of chemically active surface molecular groups, such as amino acids or sugar side chains, and generally have not only specific three-dimensional structural characteristics but also specific charge characteristics. The difference between stereogenic and nonstereogenic epitopes is that in the presence of denaturing solvents, the binding to the former disappears, but the binding to the latter does not disappear.
[0095] The antibody or antigen-binding fragment thereof of the present invention can bind to any one of the three immune domains selected from D1, D2 and D3 present in the extracellular region of FGFR3, for example, it can bind to the D1, D2 or D3 domain. Depending on the situation, the antibody or antigen-binding fragment thereof of the present invention specifically binds to domain 1 (SEQ ID NO. 184) in the FGFR3 of SEQ ID NO. 183, and does not compete with the FGF ligand for binding.
[0096] The "humanized" form of non-human (eg, mouse) antibodies is a chimeric antibody containing minimal sequence from a non-human immunoglobulin. In most cases, a humanized antibody is a human immunoglobulin in which residues from a hypervariable region of a recipient are substituted with residues from a hypervariable region of a non-human species (donor antibody) having the desired specificity, affinity, and capacity, for example, a mouse, rat, rabbit, or non-human primate.
[0097] The "human antibody" is a molecule derived from human immunoglobulin, which means that the entire amino acid sequence constituting the antibody including the complementarity determining region and the structural region is composed of human immunoglobulin.
[0098] A portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remaining chains include not only "chimeric" antibodies (immunoglobulins) that are identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, but also fragments of the antibodies that exhibit the desired biological activity.
[0099] The "variable region" of an antibody used in the present invention refers to the light chain and heavy chain portions of an antibody molecule comprising the amino acid sequence of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and the framework regions (FRs). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain.
[0100] "Complementarity determining region (CDR)" refers to the amino acid residues in the variable domain of an antibody required for antigen binding. Each variable domain generally has three CDR regions identified as CDR1, CDR2, and CDR3.
[0101] Compared with known anti-FGFR3 antibodies, the anti-FGFR3 antibodies or antigen-binding fragments thereof of the present invention are screened as antibodies having better efficacy against FGFR3-TACC3-overexpressing cancer cells, and may, for example, comprise:
[0102] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.1, a heavy chain CDR2 of SEQ ID NO.19, and a heavy chain CDR3 of SEQ ID NO.42, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.67, a light chain CDR2 of SEQ ID NO.89, and a light chain CDR3 of SEQ ID NO.110;
[0103] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.2, a heavy chain CDR2 of SEQ ID NO.20, and a heavy chain CDR3 of SEQ ID NO.43, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.68, a light chain CDR2 of SEQ ID NO.90, and a light chain CDR3 of SEQ ID NO.111;
[0104] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.3, a heavy chain CDR2 of SEQ ID NO.21, and a heavy chain CDR3 of SEQ ID NO.44, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.69, a light chain CDR2 of SEQ ID NO.91, and a light chain CDR3 of SEQ ID NO.112;
[0105] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.4, a heavy chain CDR2 of SEQ ID NO.22, and a heavy chain CDR3 of SEQ ID NO.45, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.70, a light chain CDR2 of SEQ ID NO.92, and a light chain CDR3 of SEQ ID NO.113;
[0106] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.46, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0107] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.186, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0108] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.187, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0109] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.188, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0110] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.189, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0111] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.190, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0112] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.191, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0113] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.192, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0114] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.193, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0115] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.194, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0116] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.195, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0117] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.196, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0118] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.197, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0119] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.198, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.114;
[0120] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.46, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.199;
[0121] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.46, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.200;
[0122] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.46, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.201;
[0123] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.5, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.46, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.71, a light chain CDR2 of SEQ ID NO.93, and a light chain CDR3 of SEQ ID NO.202;
[0124] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.4, a heavy chain CDR2 of SEQ ID NO.24, and a heavy chain CDR3 of SEQ ID NO.47, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.72, a light chain CDR2 of SEQ ID NO.94, and a light chain CDR3 of SEQ ID NO.115;
[0125] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.6, a heavy chain CDR2 of SEQ ID NO.25, and a heavy chain CDR3 of SEQ ID NO.48, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.73, a light chain CDR2 of SEQ ID NO.95, and a light chain CDR3 of SEQ ID NO.112;
[0126] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.7, a heavy chain CDR2 of SEQ ID NO.26, and a heavy chain CDR3 of SEQ ID NO.49, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.74, a light chain CDR2 of SEQ ID NO.96, and a light chain CDR3 of SEQ ID NO.116;
[0127] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.8, a heavy chain CDR2 of SEQ ID NO.27, and a heavy chain CDR3 of SEQ ID NO.50, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.75, a light chain CDR2 of SEQ ID NO.97, and a light chain CDR3 of SEQ ID NO.117;
[0128] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.9, a heavy chain CDR2 of SEQ ID NO.28, and a heavy chain CDR3 of SEQ ID NO.51, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.76, a light chain CDR2 of SEQ ID NO.98, and a light chain CDR3 of SEQ ID NO.118;
[0129] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.10, a heavy chain CDR2 of SEQ ID NO.29, and a heavy chain CDR3 of SEQ ID NO.52, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.77, a light chain CDR2 of SEQ ID NO.97, and a light chain CDR3 of SEQ ID NO.119;
[0130] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.11, a heavy chain CDR2 of SEQ ID NO.30, and a heavy chain CDR3 of SEQ ID NO.53, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.78, a light chain CDR2 of SEQ ID NO.99, and a light chain CDR3 of SEQ ID NO.120;
[0131] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.11, a heavy chain CDR2 of SEQ ID NO.31, and a heavy chain CDR3 of SEQ ID NO.54, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.79, a light chain CDR2 of SEQ ID NO.100, and a light chain CDR3 of SEQ ID NO.121;
[0132] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.12, a heavy chain CDR2 of SEQ ID NO.32, and a heavy chain CDR3 of SEQ ID NO.55, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.80, a light chain CDR2 of SEQ ID NO.101, and a light chain CDR3 of SEQ ID NO.122;
[0133] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.3, a heavy chain CDR2 of SEQ ID NO.33, and a heavy chain CDR3 of SEQ ID NO.56, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.81, a light chain CDR2 of SEQ ID NO.102, and a light chain CDR3 of SEQ ID NO.123;
[0134] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.13, a heavy chain CDR2 of SEQ ID NO.34, and a heavy chain CDR3 of SEQ ID NO.57, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.82, a light chain CDR2 of SEQ ID NO.103, and a light chain CDR3 of SEQ ID NO.124;
[0135] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.14, a heavy chain CDR2 of SEQ ID NO.35, and a heavy chain CDR3 of SEQ ID NO.58, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.83, a light chain CDR2 of SEQ ID NO.104, and a light chain CDR3 of SEQ ID NO.125;
[0136] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.1, a heavy chain CDR2 of SEQ ID NO.36, and a heavy chain CDR3 of SEQ ID NO.59, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.84, a light chain CDR2 of SEQ ID NO.105, and a light chain CDR3 of SEQ ID NO.126;
[0137] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.6, a heavy chain CDR2 of SEQ ID NO.23, and a heavy chain CDR3 of SEQ ID NO.60, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.69, a light chain CDR2 of SEQ ID NO.91, and a light chain CDR3 of SEQ ID NO.127;
[0138] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.15, a heavy chain CDR2 of SEQ ID NO.37, and a heavy chain CDR3 of SEQ ID NO.61, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.85, a light chain CDR2 of SEQ ID NO.89, and a light chain CDR3 of SEQ ID NO.128;
[0139] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.16, a heavy chain CDR2 of SEQ ID NO.38, and a heavy chain CDR3 of SEQ ID NO.62, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.86, a light chain CDR2 of SEQ ID NO.106, and a light chain CDR3 of SEQ ID NO.129;
[0140] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.17, a heavy chain CDR2 of SEQ ID NO.39, and a heavy chain CDR3 of SEQ ID NO.63, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.87, a light chain CDR2 of SEQ ID NO.107, and a light chain CDR3 of SEQ ID NO.130;
[0141] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.4, a heavy chain CDR2 of SEQ ID NO.19, and a heavy chain CDR3 of SEQ ID NO.64, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.88, a light chain CDR2 of SEQ ID NO.108, and a light chain CDR3 of SEQ ID NO.131;
[0142] A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO.18, a heavy chain CDR2 of SEQ ID NO.40, and a heavy chain CDR3 of SEQ ID NO.65, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO.85, a light chain CDR2 of SEQ ID NO.89, and a light chain CDR3 of SEQ ID NO.128; or
[0143] The heavy chain variable region comprises the heavy chain CDR1 of SEQ ID NO.16, the heavy chain CDR2 of SEQ ID NO.41 and the heavy chain CDR3 of SEQ ID NO.66, and the light chain variable region comprises the light chain CDR1 of SEQ ID NO.72, the light chain CDR2 of SEQ ID NO.109 and the light chain CDR3 of SEQ ID NO.132.
[0144] "Framework regions (FR)" are variable domain residues other than CDR residues. Each variable domain generally has four FRs: FR1, FR2, FR3, and FR4.
[0145] The binding affinity of anti-FGFR3 antibodies to FGFR3 is 10 -5 M to 10 -12 For example, the binding affinity of the anti-FGFR3 antibody to FGFR3 is 10 -6 M to 10 -12 M, 10 -7 M to 10 -12 M, 10 -8 M to 10 -12 M, 10 -9 M to 10 -12 M, 10 -5 M to 10 -11 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10 -11 M, 10 -10 M to 10 -11M, 10 -5 M to 10 -10 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M, 10 -9 M to 10 -10 M, 10 -5 M to 10 -9 M, 10 -6 M to 10 -9 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -9 M, 10 -5 M to 10 -8 M, 10 -6 M to 10 -8 M, 10 -7 M to 10 -8 M, 10 -5 M to 10 -7 M, 10 -6 M to 10 -7 M or 10 -5 M to 10 -6 M.
[0146] The antibody or antigen-binding fragment thereof that binds to the FGFR3 may comprise a heavy chain variable region, and the heavy chain variable region comprises one or more amino acid sequences selected from SEQ ID NO.133 to SEQ ID NO.157, and SEQ ID NO.203 to SEQ ID NO.215. In addition, the antibody or antigen-binding fragment thereof that binds to the FGFR3 may comprise a light chain variable region, and the light chain variable region comprises one or more amino acid sequences selected from SEQ ID NO.158 to SEQ ID NO.182, and SEQ ID NO.216 to SEQ ID NO.219.
[0147] In a specific embodiment of the present invention, it may include:
[0148] The heavy chain variable region of SEQ ID NO.133 and the light chain variable region of SEQ ID NO.158;
[0149] The heavy chain variable region of SEQ ID NO.134 and the light chain variable region of SEQ ID NO.159;
[0150] The heavy chain variable region of SEQ ID NO.135 and the light chain variable region of SEQ ID NO.160;
[0151] The heavy chain variable region of SEQ ID NO.136 and the light chain variable region of SEQ ID NO.161;
[0152] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.162;
[0153] The heavy chain variable region of SEQ ID NO.203 and the light chain variable region of SEQ ID NO.162;
[0154] The heavy chain variable region of SEQ ID NO.204 and the light chain variable region of SEQ ID NO.162;
[0155] The heavy chain variable region of SEQ ID NO.205 and the light chain variable region of SEQ ID NO.162;
[0156] The heavy chain variable region of SEQ ID NO.206 and the light chain variable region of SEQ ID NO.162;
[0157] The heavy chain variable region of SEQ ID NO.207 and the light chain variable region of SEQ ID NO.162;
[0158] The heavy chain variable region of SEQ ID NO.208 and the light chain variable region of SEQ ID NO.162;
[0159] The heavy chain variable region of SEQ ID NO.209 and the light chain variable region of SEQ ID NO.162;
[0160] The heavy chain variable region of SEQ ID NO.210 and the light chain variable region of SEQ ID NO.162;
[0161] The heavy chain variable region of SEQ ID NO.211 and the light chain variable region of SEQ ID NO.162;
[0162] The heavy chain variable region of SEQ ID NO.212 and the light chain variable region of SEQ ID NO.162;
[0163] The heavy chain variable region of SEQ ID NO.213 and the light chain variable region of SEQ ID NO.162;
[0164] The heavy chain variable region of SEQ ID NO.214 and the light chain variable region of SEQ ID NO.162;
[0165] The heavy chain variable region of SEQ ID NO.215 and the light chain variable region of SEQ ID NO.162;
[0166] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.216;
[0167] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.217;
[0168] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.218;
[0169] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.219;
[0170] The heavy chain variable region of SEQ ID NO.138 and the light chain variable region of SEQ ID NO.163;
[0171] The heavy chain variable region of SEQ ID NO.139 and the light chain variable region of SEQ ID NO.164;
[0172] The heavy chain variable region of SEQ ID NO.140 and the light chain variable region of SEQ ID NO.165;
[0173] The heavy chain variable region of SEQ ID NO.141 and the light chain variable region of SEQ ID NO.166;
[0174] The heavy chain variable region of SEQ ID NO.142 and the light chain variable region of SEQ ID NO.167;
[0175] The heavy chain variable region of SEQ ID NO.143 and the light chain variable region of SEQ ID NO.168;
[0176] The heavy chain variable region of SEQ ID NO.144 and the light chain variable region of SEQ ID NO.169;
[0177] The heavy chain variable region of SEQ ID NO.145 and the light chain variable region of SEQ ID NO.170;
[0178] The heavy chain variable region of SEQ ID NO.146 and the light chain variable region of SEQ ID NO.171;
[0179] The heavy chain variable region of SEQ ID NO.147 and the light chain variable region of SEQ ID NO.172;
[0180] The heavy chain variable region of SEQ ID NO.148 and the light chain variable region of SEQ ID NO.173;
[0181] The heavy chain variable region of SEQ ID NO.149 and the light chain variable region of SEQ ID NO.174;
[0182] The heavy chain variable region of SEQ ID NO.150 and the light chain variable region of SEQ ID NO.175;
[0183] The heavy chain variable region of SEQ ID NO.151 and the light chain variable region of SEQ ID NO.176;
[0184] The heavy chain variable region of SEQ ID NO.152 and the light chain variable region of SEQ ID NO.177;
[0185] The heavy chain variable region of SEQ ID NO.153 and the light chain variable region of SEQ ID NO.178;
[0186] The heavy chain variable region of SEQ ID NO.154 and the light chain variable region of SEQ ID NO.179;
[0187] The heavy chain variable region of SEQ ID NO.155 and the light chain variable region of SEQ ID NO.180;
[0188] The heavy chain variable region of SEQ ID NO.156 and the light chain variable region of SEQ ID NO.181; or
[0189] The heavy chain variable region of SEQ ID NO.157 and the light chain variable region of SEQ ID NO.182.
[0190] scFv
[0191] scFv is a structure composed of a single polypeptide chain comprising the VH and VL domains of an antibody, which is an antibody fragment. scFv may further comprise a polypeptide linker between the VH domain and the VL domain so that a desired structure can be formed for antigen binding.
[0192] In one embodiment, the VH and VL domains of a single-chain Fv (scFv) comprising the VH and VL domains of an antibody may be connected by a linker. A heavy chain variable region comprising one or more amino acid sequences selected from SEQ ID NO.133 to SEQ ID NO.157, SEQ ID NO.203 to SEQ ID NO.215 may be connected to a light chain variable region comprising one or more amino acid sequences selected from SEQ ID NO.158 to SEQ ID NO.182, SEQ ID NO.216 to SEQ ID NO.219 by a linker.
[0193] In a specific embodiment of the present invention, it may include:
[0194] The heavy chain variable region of SEQ ID NO.133 and the light chain variable region of SEQ ID NO.158;
[0195] The heavy chain variable region of SEQ ID NO.134 and the light chain variable region of SEQ ID NO.159;
[0196] The heavy chain variable region of SEQ ID NO.135 and the light chain variable region of SEQ ID NO.160;
[0197] The heavy chain variable region of SEQ ID NO.136 and the light chain variable region of SEQ ID NO.161;
[0198] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.162;
[0199] The heavy chain variable region of SEQ ID NO.203 and the light chain variable region of SEQ ID NO.162;
[0200] The heavy chain variable region of SEQ ID NO.204 and the light chain variable region of SEQ ID NO.162;
[0201] The heavy chain variable region of SEQ ID NO.205 and the light chain variable region of SEQ ID NO.162;
[0202] The heavy chain variable region of SEQ ID NO.206 and the light chain variable region of SEQ ID NO.162;
[0203] The heavy chain variable region of SEQ ID NO.207 and the light chain variable region of SEQ ID NO.162;
[0204] The heavy chain variable region of SEQ ID NO.208 and the light chain variable region of SEQ ID NO.162;
[0205] The heavy chain variable region of SEQ ID NO.209 and the light chain variable region of SEQ ID NO.162;
[0206] The heavy chain variable region of SEQ ID NO.210 and the light chain variable region of SEQ ID NO.162;
[0207] The heavy chain variable region of SEQ ID NO.211 and the light chain variable region of SEQ ID NO.162;
[0208] The heavy chain variable region of SEQ ID NO.212 and the light chain variable region of SEQ ID NO.162;
[0209] The heavy chain variable region of SEQ ID NO.213 and the light chain variable region of SEQ ID NO.162;
[0210] The heavy chain variable region of SEQ ID NO.214 and the light chain variable region of SEQ ID NO.162;
[0211] The heavy chain variable region of SEQ ID NO.215 and the light chain variable region of SEQ ID NO.162;
[0212] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.216;
[0213] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.217;
[0214] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.218;
[0215] The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.219;
[0216] The heavy chain variable region of SEQ ID NO.138 and the light chain variable region of SEQ ID NO.163;
[0217] The heavy chain variable region of SEQ ID NO.139 and the light chain variable region of SEQ ID NO.164;
[0218] The heavy chain variable region of SEQ ID NO.140 and the light chain variable region of SEQ ID NO.165;
[0219] The heavy chain variable region of SEQ ID NO.141 and the light chain variable region of SEQ ID NO.166;
[0220] The heavy chain variable region of SEQ ID NO.142 and the light chain variable region of SEQ ID NO.167;
[0221] The heavy chain variable region of SEQ ID NO.143 and the light chain variable region of SEQ ID NO.168;
[0222] The heavy chain variable region of SEQ ID NO.144 and the light chain variable region of SEQ ID NO.169;
[0223] The heavy chain variable region of SEQ ID NO.145 and the light chain variable region of SEQ ID NO.170;
[0224] The heavy chain variable region of SEQ ID NO.146 and the light chain variable region of SEQ ID NO.171;
[0225] The heavy chain variable region of SEQ ID NO.147 and the light chain variable region of SEQ ID NO.172;
[0226] The heavy chain variable region of SEQ ID NO.148 and the light chain variable region of SEQ ID NO.173;
[0227] The heavy chain variable region of SEQ ID NO.149 and the light chain variable region of SEQ ID NO.174;
[0228] The heavy chain variable region of SEQ ID NO.150 and the light chain variable region of SEQ ID NO.175;
[0229] The heavy chain variable region of SEQ ID NO.151 and the light chain variable region of SEQ ID NO.176;
[0230] The heavy chain variable region of SEQ ID NO.152 and the light chain variable region of SEQ ID NO.177;
[0231] The heavy chain variable region of SEQ ID NO.153 and the light chain variable region of SEQ ID NO.178;
[0232] The heavy chain variable region of SEQ ID NO.154 and the light chain variable region of SEQ ID NO.179;
[0233] The heavy chain variable region of SEQ ID NO.155 and the light chain variable region of SEQ ID NO.180;
[0234] The heavy chain variable region of SEQ ID NO.156 and the light chain variable region of SEQ ID NO.181; or
[0235] The heavy chain variable region of SEQ ID NO.157 and the light chain variable region of SEQ ID NO.182.
[0236] The linker may be a peptide linker and may have a length of about 10-25 aa. For example, it may include hydrophilic amino acids such as glycine and / or serine, but is not limited thereto.
[0237] Specifically, the linker may include, for example, (GS) n 、(GGS) n 、(GSGGS) n or (G n S) m (n, m are 1 to 10, respectively), but the linker can be, for example, (G n S) m (n and m are 1 to 10, respectively). Specifically, the linker may comprise GGGGS, for example, GGGGSGGGGSGGGGS of SEQ ID NO. 185 repeated three times.
[0238] "Phage display" is a technique for displaying variant polypeptides as fusion proteins that are at least part of a coat protein on the surface of a bacteriophage, e.g., a fibrous phage particle. The usefulness of phage display is that by targeting large libraries of randomized protein variants, sequences that bind to a target antigen with high affinity can be rapidly and efficiently sorted. The technique of displaying peptide and protein libraries on phage has been used to screen millions of polypeptides for those with specific binding properties.
[0239] Phage display technology provides a powerful tool for forming and screening novel proteins that bind to specific ligands (examples: antigens). By using phage display technology, a large library of protein variants is formed, and sequences that bind to target antigens with high affinity can be rapidly classified. Nucleic acids encoding variant polypeptides are fused to nucleic acid sequences encoding viral coat proteins, for example, the viral coat proteins are gene III proteins or gene VIII proteins. Monovalent phage display systems have been developed that fuse nucleic acid sequences encoding proteins or polypeptides to nucleic acid sequences encoding a part of gene III proteins. In monovalent phage display systems, gene fusions are expressed at low levels, and wild-type gene III proteins are also expressed, thereby maintaining particle infectivity.
[0240] In the development of antibody phage display libraries, it is important to demonstrate the expression of peptides on the surface of fibrous phages and the expression of functional antibody fragments in the periplasm of E. coli. Libraries of antibodies or antigen-binding polypeptides are prepared by a variety of methods, for example, by inserting random DNA sequences to alter individual genes or by cloning related gene lines. Using libraries as objects, the expression of antibodies or antigen-binding proteins with desired characteristics can be screened.
[0241] Compared with the common hybridoma and recombinant methods for preparing antibodies with desired characteristics, phage display technology has several advantages. This technology can form a large antibody library with various sequences in a short time without using animals. The preparation of hybridomas or the preparation of humanized antibodies may require a preparation cycle of several months. In addition, there is no need for immunity at all, so phage antibody libraries can also form antibodies to antigens with low toxicity or antigenicity. Phage antibody libraries can also be used to form and confirm new therapeutic antibodies.
[0242] Techniques for generating human antibodies from immune, non-immune humans, germline sequences, or unsensitized B cell Ig repertoires using phage display libraries can be used. Unsensitized or non-immune antigen binding libraries can be prepared using various lymphoid tissues.
[0243] Techniques that can identify and isolate high-affinity antibodies from phage display libraries are important for the isolation of novel therapeutic antibodies. Techniques for isolating high-affinity antibodies from libraries may depend on the size of the library, the efficiency of production in bacterial cells, and the diversity of the library. The size of the library is reduced due to inefficient production caused by the misfolding of the antibody or antigen-binding protein and the presence of stop codons. When the antibody or antigen-binding domain is not properly folded, expression in bacterial cells may be inhibited. Alternating mutations of residues on the surface of the variable / constant interface or in the screened CDR residues can improve expression. The sequence of the framework region is an element used to provide correct folding when forming an antibody phage library in bacterial cells.
[0244] It is important to form various libraries of antibodies or antigen binding proteins in the isolation of high affinity antibodies. It has been found that the CDR3 region is often involved in antigen binding. The CDR3 region on the heavy chain is very diverse in terms of size, sequence and structural stereomorphology, so it can be used to prepare various libraries.
[0245] In addition, diversity can be generated by randomizing the CDR regions of the variable heavy and light chains using all 20 amino acids at each site. When all 20 amino acids are used, highly diverse variant antibody sequences are formed and the chance of identifying new antibodies can be increased.
[0246] To the extent that FGFR3 can be specifically recognized, the antibodies or antibody fragments of the present invention not only include the sequence of the anti-FGFR3 antibody of the present invention recorded in this specification, but also may include its biological equivalents. For example, in order to further improve the binding affinity and / or other biological properties of the antibody, the amino acid sequence of the antibody may be further changed. Such deformations include, for example, deletions, insertions and / or substitutions of residues in the amino acid sequence of the antibody. Such amino acid variations are formed based on the relative similarity of amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc. According to the analysis of the size, morphology and type of amino acid side chain substituents, it can be seen that arginine, lysine and histidine are all positively charged residues; alanine, glycine and serine have similar sizes; phenylalanine, tryptophan and tyrosine have similar morphologies. Therefore, based on the above considerations, it can be considered that arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine are biologically functional equivalents.
[0247] Taking into account the variation with the above-mentioned biologically equivalent activity, the antibody of the present invention or the nucleic acid molecule encoding the antibody is interpreted as also comprising a sequence showing substantial identity with the sequence recorded in SEQ ID NO. The above-mentioned substantial identity means that the sequence of the present invention and any other sequence are aligned as much as possible, and when the aligned sequences are analyzed using the algorithm commonly used in the art, a sequence showing a minimum of 90% homology, preferably a minimum of 95% homology, a homology of more than 96%, a homology of more than 97%, a homology of more than 98%, or a homology of more than 99% is shown. Alignment methods for sequence comparison are well known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) can be accessed from NBCI and others and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn, and tblastx on the web. BLAST can be accessed from www.ncbi.nlm.nih.gov / BLAST / . Sequence homology comparison methods using this program can be identified at www.ncbi.nlm.nih.gov / BLAST / blast_help.html.
[0248] Based on this, compared with the sequence or the whole recorded and clearly shown in the specification, the antibody or its antigen-binding fragment of the present invention can have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology. This homology can be determined by sequence comparison and / or arrangement according to methods known in the art. For example, the percentage sequence homology of the nucleic acid or protein of the present invention can be determined using a sequence comparison algorithm (i.e., BLAST or BLAST 2.0), manual arrangement, or visual inspection.
[0249] Another aspect of the present invention relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof. The nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention is isolated so that the antibody or antigen-binding fragment thereof can be produced in a recombinant manner.
[0250] "Nucleic acid" has the meaning of including all DNA (gDNA and cDNA) and RNA molecules, and the nucleotides as the basic constituent units in nucleic acids include not only natural nucleotides, but also analogs with modified sugar or base sites. The sequences of the nucleic acids encoding the heavy chain and light chain variable regions of the present invention can be modified. The modifications include addition, deletion, or non-conservative substitution or conservative substitution of nucleotides.
[0251] The DNA encoding the antibody can be easily separated or synthesized by using common molecular biological methods (e.g., by using oligonucleotide probes that can specifically bind to the antibody and the DNA encoding the heavy and light chains), isolating the nucleic acid, and inserting the nucleic acid into a replicable vector for further cloning (amplification of the DNA) or further expression. Based on this, another aspect of the present invention relates to a recombinant expression vector comprising the nucleic acid.
[0252] The term "vector" used in this specification is a means for expressing a target gene in a host cell, and includes viral vectors such as plasmid vectors, cosmid vectors, phage vectors, adenoviral vectors, retroviral vectors, and adeno-associated viral vectors. The components of the vector generally include one or more of the following, but are not limited thereto: a signal sequence, an origin of replication, one or more antibiotic resistance marker genes, an enhancer element, a promoter, and a transcription termination sequence. Like a promoter and a transcription termination sequence, the nucleic acid encoding the antibody may be operably linked.
[0253] "Operably linked" refers to the functional combination between a nucleic acid expression regulatory sequence (e.g., a series of promoters, signal sequences or transcriptional regulatory factor binding sites) and other nucleic acid sequences, so that the regulatory sequence can regulate the transcription and / or translation of the other nucleic acid sequence.
[0254] When prokaryotic cells are used as hosts, they usually contain strong promoters that can carry out transcription (for example, tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.), ribosome binding sites for initiating translation, and transcription / translation termination sequences. In addition, for example, when eukaryotic cells are used as hosts, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter, β-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, HSV tk promoter, mouse mammary tumor virus (MMTV) promoter, HIV LTR promoter, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, and Rous sarcoma virus (RSV) promoter) can be used, and they usually have a polyadenylation sequence as a transcription termination sequence.
[0255] Depending on the situation, the vector can also be fused to another sequence to facilitate the purification of the antibody expressed from the vector. The fused sequence is, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).
[0256] The vector contains an antibiotic resistance gene commonly used in the art as a selection marker, for example, there are resistance genes to ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline.
[0257] Another aspect of the present invention relates to a host cell transfected by the recombinant expression vector. The host cell used to form the antibody of the present invention can be a prokaryotic organism, yeast or a higher eukaryotic organism cell, but is not limited thereto.
[0258] Prokaryotic host cells such as Bacillus strains such as Escherichia coli, Bacillus subtilis, and Bacillus thuringiensis; Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis, and Staphylococcus (e.g., Staphylococcus carnosus) can be utilized.
[0259] However, animal cells are of greatest interest, and examples of useful host cell lines may be COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S, or HT1080, but are not limited thereto.
[0260] Another aspect of the present invention relates to a method for preparing an antibody or an antigen-binding fragment thereof that specifically binds to FGFR3, the method comprising the following steps: culturing the host cell to form the antibody; and isolating and purifying the formed antibody.
[0261] The host cells can be cultured in a variety of culture media. Commercially available culture media can be used as culture media without limitation. All other necessary supplements known to those skilled in the art may also be included at appropriate concentrations. For expression, culture conditions such as temperature, pH, etc. have been used with the selected host cells, which will be apparent to those skilled in the art.
[0262] The antibody or antigen-binding fragment thereof can be recovered, for example, by removing impurities by centrifugation or ultrafiltration, and the product can be purified by, for example, affinity chromatography, etc. As for additional purification techniques, for example, anion or cation exchange chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography, etc. can be used.
[0263] Bispecific or multispecific antibodies
[0264] Another aspect of the present invention relates to a bispecific antibody or multispecific antibody comprising the antibody or antigen-binding fragment thereof.
[0265] A bispecific antibody refers to an antibody that has the ability to bind or antagonize more than one target, and refers to a form in which antibodies that have the ability to bind or antagonize two different targets are combined, or an antibody that has the ability to bind to one target and a substance that has the ability to antagonize another target are combined.
[0266] A multispecific antibody refers to an antibody that has binding specificity for at least three or more different antigens. A multispecific antibody may include an antibody with three or more specificities, for example, a trispecific antibody, a tetraspecific antibody, or an antibody targeting four or more targets.
[0267] Antibodies belonging to bispecific antibodies or multispecific antibodies can be divided into scFv-based antibodies, Fab-based antibodies, IgG-based antibodies, etc. In the case of bispecific antibodies or multispecific antibodies, two or more signals can be inhibited or amplified at the same time, so it can be more effective than the case of inhibiting / amplifying one signal, and compared with the case of treating each signal with each signal inhibitor, it can be administered at a lower dose, and two or more signals in the same time and space can be inhibited / amplified.
[0268] Methods for preparing bispecific or multispecific antibodies are well known. Traditionally, recombinant production of bispecific antibodies is based on the co-expression of two or more heavy chains with different specificities as two or more immunoglobulin heavy chain / light chain pairs.
[0269] In the case of scFv-based bispecific antibodies or multispecific antibodies, the VL and VH of different scFvs can be combined with each other to prepare hybrid scFvs in the form of heterodimers, thereby preparing bispecific antibodies (diabody). Different scFvs can be connected to each other to prepare tendon scFvs. The CH1 and CL of Fab can be expressed at the end of each scFv to prepare heterodimeric miniantibodies. The structure of the heterodimer can be changed to a "knob into hole" form by replacing some amino acids in the CH3 domain, which is the homodimeric domain of Fc, and expressing these changed CH3 domains at the ends of different scFvs to prepare heterodimeric scFv miniantibodies.
[0270] In the case of bispecific antibodies or multispecific antibodies based on Fab, a single Fab′ for a specific antigen can be prepared as a heterodimeric Fab form by combining disulfide bonds or mediators, and the antigen binding valency can be 2 by expressing scFv for different antigens at the end of the heavy chain or light chain of a specific Fab, or a hinge region can be provided between Fab and scFv to prepare a homodimer form with 4 antigen binding valencies. In addition, by fusing scFv for different antigens at the light chain end and the heavy chain end of Fab, a dual-target bibody with 3 antigen binding valencies can be obtained, and by fusing different scFvs at the light chain end and the heavy chain end of Fab, a three-target bibody with 3 antigen binding valencies can be obtained, and it can be obtained by chemically joining 3 different Fabs.
[0271] In the case of bispecific antibodies or multispecific antibodies based on IgG, the following method is known: TrionPharma re-hybridizes mouse and rat hybridomas to prepare hybridized hybridomas, also known as quadromas, to produce bispecific antibodies. In addition, bispecific antibodies can be prepared in the form of heterodimers by changing some amino acids of the CH3 homodimer domain of Fc for different heavy chains while sharing the light chain portion, and preparing bispecific antibodies in the so-called 'Holes and Knob' form. In addition to bispecific antibodies in the form of heterodimers, two different scFvs can be fused and expressed in the constant domain to replace the variable domains of the light chain and heavy chain of IgG, respectively, to prepare (scFv)4-IgG in the form of homodimers. In addition, ImClone reportedly prepared a bispecific antibody based on IMC-1C11, a chimeric monoclonal antibody against human VEGFR-2, by fusing only a single variable domain against mouse platelet-derived growth factor receptor-α to the amino terminus of the light chain of the antibody. In addition, antibodies with multiple antigen-binding valencies for CD20 can be prepared by the so-called 'dock and lock (DNL)' method using the dimerization and docking domain (DDD) of the R subunit of protein kinase A (PKA) and the anchoring domain (anchoring domain) of PKA.
[0272] Various recombinant antibody formats have been developed, for example, bispecific antibodies or multispecific antibodies with 2 or more valencies, 3 or more valencies or 4 or more valencies have been developed. For example, the bivalent or more, trivalent or more, or more than 4-valent antibodies described in International Patent Application Publication Nos. WO2001 / 077342, WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254, WO2010 / 112193, WO2010 / 115589, WO2010 / 136172, WO2010 / 145792, WO2010 / 145793, and WO2011 / 117330 are also included. A divalent or higher-valent antibody, a trivalent or higher-valent antibody, or a tetravalent or higher-valent antibody means that two or more binding domains, three or more binding domains, or four or more binding domains are present in the antibody molecule, respectively.
[0273] In a specific embodiment, the bispecific antibody or multispecific antibody of the present invention can specifically comprise the anti-FGFR3 antibody or antigen-binding fragment in the form of an IgG complete antibody or fragment thereof, for example, in the form of a single chain Fv, V H Domain and / or V L The forms of domains, Fab or (Fab)2 are included.
[0274] In addition, with respect to antibodies targeting the FGFR3 and antibodies that bind to other targets, for example, antibodies targeting one or more selected from PD-1, PD-L1, BTLA, CTLA-4, VISTA, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, MARCO, specifically IgG complete antibodies or fragments thereof, for example, single-chain Fv, V n Domain and / or V L domain, Fab or (Fab)2 format.
[0275] By means of the bispecific antibody or multispecific antibody of the present invention, in addition to FGFR3, additional binding specificities induced or mediated by other targets can be ensured.
[0276] For example, the bispecific antibodies of the present invention can simultaneously target FGFR3 and one or more selected from PD-1, PD-L1, BTLA, CTLA-4, VISTA, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
[0277] For example, the multispecific antibodies of the present invention can simultaneously target FGFR3 and two or more selected from PD-1, PD-L1, BTLA, CTLA-4, VISTA, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
[0278] Immune cell engagement with bispecific or multispecific antibodies
[0279] Another aspect of the present invention relates to an immune cell engaging bispecific antibody or multispecific antibody comprising an antibody scFv and an scFv consisting of a second binding domain comprising one or more antibody scFvs that bind to an immune cell activating antigen.
[0280] By engaging the bispecific antibody or multispecific antibody by the immune cell, a cytolytic synapse between the cytotoxic T cell and the cancer target cell is temporarily induced, thereby releasing toxic substances.
[0281] In one embodiment, the immune cells may be one or more selected from T cells, NK cells, cytokine induced killer cells (CIK), activated cytotoxic T lymphocytes (CTL), macrophages, tumor-infiltrating T cells (TIL), and dendritic cells.
[0282] In one embodiment, the immune cell activation antigen can be selected from the following antigens, and the antibody binding to the antigen can play an immune cell engagement role:
[0283] T cell activation antigen is CD3, TCRα, TCRβ, TCRγ, TCRξ, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226;
[0284] The NK cell activating antigen is NKp30, NKp40, NKp44, NKp46, NKG2D, DNAM1, DAP10, CD16 (e.g., CD16a, CD16b), CRTAM, CD27, PSGL1, CD96, CD100 (SEMA4D), NKp80, CD244 (SLAMF4 or 2B4), SLAMF6, SLAMF7, KIR2DS2, KIR2DS4, KIR3DS1, KIR2DS3, KIR2DS5, KIR2DS1, CD94, NKG2C, NKG2E or CD160;
[0285] B cell activation antigens are OX40, CD40, or CD70;
[0286] The macrophage activation antigen is a CD2 agonist, CD40, CD70, a Toll-like receptor (TCR) agonist, CD47, STING, or OX40L; or
[0287] The dendritic cell activating antigen is a CD2 agonist, an OX40, OX40L, 41BB agonist, a TCR agonist, a CD47 agonist or a STING agonist.
[0288] The immune cell engager is specifically described in U.S. Patent Application Publication No. 2017 / 0368169, which can be introduced into the present invention as a reference.
[0289] Specifically, the immune cell engaging bispecific antibody or multispecific antibody comprises a tandem scFv and can bind to the following antigens and surface antigens on cancer cells. The surface antigen on the cancer cell is FGFR3 targeted by the antibody of the present invention:
[0290] CD3, TCRα, TCRβ, TCRγ, TCRξ, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226;
[0291] NKp30, NKp40, NKp44, NKp46, NKG2D, DNAM1, DAP10, CD16 (e.g., CD16a, CD16b), CRTAM, CD27, PSGL1, CD96, CD100 (SEMA4D), NKp80, CD244 (SLAMF4 or 2B4), SLAMF6, SLAMF7, KIR2DS2, KIR2DS4, KIR3DS1, KIR2DS3, KIR2DS5, KIR2DS1, CD94, NKG2C, NKG2E, or CD160;
[0292] OX40, CD40, or CD70;
[0293] CD2 agonist, CD40, CD70, TCR (Toll-like Receptor) agonist, CD47, STING or OX40L; or
[0294] CD2 agonist, OX40, OX40L, 41BB agonist, TCR agonist, CD47 agonist or STING agonist.
[0295] The immune cell engaging bispecific antibody or multispecific antibody may comprise structures such as VL(FGFR3)-VH(FGFR3)-VH(CD3 or CD16A)-VL(CD3 or CD16A), VH(FGFR3)-VL(FGFR3)-VH(CD3 or CD16A)-VL(CD3 or CD16A), VH(CD3 or CD16A)-VL(CD3 or CD16A)-VH(FGFR3)-VL(FGFR3) or VH(CD3 or CD16A)-VL(CD3 or CD16A)-VL(FGFR3)-VH(FGFR3).
[0296] The scFv, for example, comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises one or more amino acid sequences selected from SEQ ID NO.133 to SEQ ID NO.157, SEQ ID NO.203 to SEQ ID NO.215, and the light chain variable region comprises one or more amino acid sequences selected from SEQ ID NO.158 to SEQ ID NO.182, SEQ ID NO.216 to SEQ ID NO.219, and the heavy chain variable region and the light chain variable region can be connected by a linker.
[0297] The linker may be a peptide linker and may have a length of about 10-25 aa. For example, it may comprise hydrophilic amino acids such as glycine and / or serine.
[0298] The linker may for example comprise (GS) n 、(GGS) n 、(GSGGS) n or (G n S) m (n, m are 1 to 10, respectively), but the linker can be, for example, (G n S) m (n and m are 1 to 10, respectively). Specifically, the linker may comprise GGGGS, for example, GGGGSGGGGSGGGGS of SEQ ID NO. 185 repeated three times.
[0299] As an example of the immune cell-engaging bispecific or multispecific antibodies, blinatumomab (Amgen) that binds to CD3 and CD19; solitomab (Amgen) that binds to CD3 and EpCAM; MEDI 565 (MedImmune, Amgen) that binds to CD3 and CEA; and BAY2010112 (Bayer, Amgen) that binds to CD3 and PSMA. Exemplary DARTs include MGD006 (Macrogenics) that binds to CD3 and CD123; and MGD007 (Macrogenics) that binds to CD3 and gpA33. Exemplary TandAbs may include AFM11 (Affimed Therapeutics) that binds to CD3 and CD19; and AFM13 (Affimed Therapeutics) that binds to CD30 and CD16A.
[0300] Antibody-drug conjugates (ADCs)
[0301] Another aspect of the present invention relates to an antibody-drug conjugate (ADC) in which the antibody or antigen-binding fragment thereof is conjugated to a drug.
[0302] Before delivering the anticancer drug to the targeted cancer cells, the anticancer drug of the antibody-drug conjugate should be stably bound to the antibody. The drug delivered to the target should be freed from the antibody, thereby inducing the death of the target cells. To this end, the drug should be stably bound to the antibody and should have sufficient cytotoxicity to induce the death of the target cells when freed from the target cells.
[0303] In one embodiment, the antibody can be combined with a drug via a linker. The linker is a site connecting the anti-FGFR3 antibody and the drug, and should have a morphology that can be cut under intracellular conditions, that is, the drug can be released from the antibody in the intracellular environment, and the antibody is stable in the systemic circulation while reflecting the long half-life of the antibody, and the combination of the linker and the drug should not affect the stability and pharmacokinetics of the antibody.
[0304] The linker may, for example, comprise a cleavable linker or a non-cleavable linker. In the case of a cleavable linker, such as a peptide linker, it can be cleaved by intracellular peptidases or proteases, for example, it can be cleaved by lysosomal or endosomal proteases, and in the case of a non-cleavable linker, such as a thioether linker, the antibody can release the drug after non-selective degradation by intracellular hydrolysis.
[0305] In one embodiment, the cleavable linker may comprise a peptide linker. The peptide linker has a length of at least 2 amino acids. For example, it may comprise a dipeptide of Val-Cit, Val-Ala or Val-Cit, or Phe-Leu or Gly-Phe-Leu-Gly. Examples of linkers are specifically described in International Patent Application Publication No. WO2004 / 010957, and may be introduced into the present invention as a reference.
[0306] The antibody-drug conjugate is internalized into the cancer cell through the endosomal-lysosomal pathway after the antigen targeting the cancer cell binds to the antibody region of the ADC to form an ADC-antigen complex. In this case, the intracellular release of the cytotoxic drug is regulated according to the internal environment of the endosome / lysosome.
[0307] In one embodiment, the cleavable linker is pH sensitive and can be sensitive to hydrolysis at a specific pH value. Generally, a pH sensitive linker means that it can be hydrolyzed under acidic conditions. For example, it can be an acid-labile linker that is hydrolyzed in a lysosome, such as a hydrazone, a semicarbazone, a thiosemicarbazone, a cis-aconitic amide, an orthoester, an acetal, a ketal, and the like.
[0308] In another embodiment, the linker can be cleaved under reducing conditions, for example, a disulfide linker can belong to this. Various disulfide bonds can be formed by using N-succinimidyl-S-acetylthioacetate (SATA), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl-3-(2-pyridyldithio)butyrate (SPDB) and N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene (SMPT). This disulfide linker can be degraded by thiol-disulfide exchange of intracellular glutathione.
[0309] The drug and / or drug-linker can be randomly joined by the lysine of the antibody, or can be joined by the cysteine exposed when the disulfide bond chain is reduced. Depending on the situation, it can be joined by a label prepared by genetic engineering, for example, the linker-drug can be combined by the cysteine present in the peptide or protein. The label prepared by genetic engineering, for example, the peptide or protein can contain an amino acid motif that can be recognized by an isoprenoid transferase. The peptide or protein has a deletion at the carboxyl terminus of the peptide or protein, or has an addition of a covalent bond through a spacer unit at the carboxyl (C) terminus of the peptide or protein.
[0310] The peptide or protein can be directly covalently bonded to the amino acid motif or covalently bonded to the spacer unit to be linked to the amino acid motif. The amino acid spacer unit consists of 1-20 amino acids, wherein the glycine unit is preferred.
[0311] The isoprenoid transferase can be, for example, farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase), FTase and GGTaseI can recognize the CAAX motif, and GGTase II can recognize the XXCC, XCXC or CXX motif (wherein, C is cysteine, A is an aliphatic amino acid, and X is an amino acid that determines the substrate specificity of the isoprenoid transferase).
[0312] In another embodiment, the linker may comprise a β-glucuronide linker, which is mostly present in lysosomes or is recognized and hydrolyzed by β-glucuronidase overexpressed in several tumor cells. Unlike peptide linkers, it has the advantage of increasing the solubility of the antibody-drug complex when combined with a highly hydrophobic drug due to its high hydrophilicity.
[0313] For this purpose, the β-glucuronide linkers disclosed in International Patent Application Publication No. WO2015 / 182984, for example, β-glucuronide linkers containing a self-immolative group, can be used, and the above document can be incorporated as a reference.
[0314] Depending on the circumstances, the linker can be, for example, a non-cleavable linker that releases the drug only by an antibody hydrolysis step in the cell, for example, to produce an amino acid-linker-drug complex. This type of linker can be a thioether group or a maleimidocaproyl group, and can maintain stability in the blood.
[0315] According to one embodiment of the present invention, the linker-drug can be conjugated by randomly conjugating the cysteine exposed by reducing the disulfide bond chain of the antibody or by introducing an antibody terminal binding peptide having the sequence GGGGGGGCVIM.
[0316] The drug (comprising D of chemical formula (1)) can be combined with an antibody in the form of a preparation showing a pharmacological effect, and can specifically be a chemotherapeutic agent, a toxin, a microRNA (miRNA), a small interfering ribonucleic acid (siRNA), a short hairpin RNA (shRNA) or a radioactive isotope. The chemotherapeutic agent can be, for example, a cytotoxic agent or an immunosuppressant. Specifically, it can include a microtubule inhibitor, a mitotic inhibitor, a topoisomerase inhibitor or a chemotherapeutic agent that can function as a DNA intercalator. In addition, it can include drugs for treating cancer, inflammation or immune diseases. For example, it can include an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an anthelmintic or a combination thereof.
[0317] The anticancer agent can be, for example, selected from maytansine compounds, auristatins (including MMAE, MMAF), aminopterin, actinomycin, bleomycin, talithromycin, camptothecin, N8-acetyl spermidine, 1-(2-chloroethyl)-1,2-dimethylsulfonyl hydrazide, esperamicin, etoposide, 6-mercaptopurine, dolestacin, trichothecenes, calicheamicin, taxol, taxane, paclitaxel, docetaxel, methotrexate, vincristine, vinblastine, doxorubicin, melphalan, mitomycin A, mitomycin C, chlorambucil, duocarcin, L-asparaginase , mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosourea, cisplatin, carboplatin, mitomycin, dacarbazine, procarbazine, topotecan, nitrogen mustard, cytoxan, etoposide, 5-fluorouracil, bischloroethylnitrosourea,CNU), irinotecan, camptothecin, bleomycin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinorelbine, chlorambucil, melphalan, carmustine, lomustine, busulfan, treosulfan, decarbazine, etoposide, teniposide, topotecan, 9-aminocamptothecin, crisnatol, mitomycin C C), trimetrexate, mycophenolic acid, tiazofurin, ribavirin, 5-ethynyl-1-beta-Dribofuranosylimidazole-4-carboxamide,EICAR), hydroxyurea sulfate, deferoxamine, floxuridine, doxifluridine, raltitrexed, cytarabine (ara C), cytosine arabinoside, fludarabine, tamoxifen, raloxifene, megestrol, goserelin, leuprolide acetate, flutamide, bicalutamide, EB1089, CB1093, KH1060, verteporfin, phthalocyanine, photosensitizer Pe4 (photosensitizer Pe4), demethoxy-hypocrellin A, interferon-α, interferon-γ, tumor necrosis factor, gemcitabine, velcade, revamid, thalamid, lovastatin, 1-methyl-4-phenylpyridiniumion, staurosporine, actinomycin D, dactinomycin, bleomycin A2 A2), bleomycin B2, peplomycin, epirubicin, pirarubicin, zorubicin, mitoxantrone, verapamil, thapsigargin, nuclease, and one or more toxins derived from bacteria, animals, or plants, but not limited thereto.
[0318] The anti-inflammatory drugs may include steroid preparations that reduce inflammation or swelling by binding to glucocorticoid receptors, non-steroidal anti-inflammatory drugs (NSAIDs) that relieve pain by corresponding to cyclooxygenase (COX) that synthesizes prostaglandins that cause inflammation, or immune-specific anti-inflammatory drugs (ImSAIDs) that change the activation and transport of inflammatory cells, but are not limited thereto.
[0319] The immune disease therapeutic agent may include azathioprine, chlorambucil, cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine or methotrexate, but is not limited thereto.
[0320] Specifically, the immunosuppressant may be tacrolimus, a calcineurin inhibitor, mycophenolate mofetil, a gene synthesis inhibitor, or prednisone, an anti-inflammatory steroid, but is not limited thereto.
[0321] Depending on the circumstances, in order to form covalent bonds with electrophilic groups on linkers and linker reagents, the drug may contain one or more reactive nucleophilic groups selected from amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazide, hydrazine carboxylate and aromatic hydrazide groups.
[0322] In a specific embodiment of the present invention, an ADC in which the antibody or antigen-binding fragment thereof of the present invention is linked to a drug, for example, an ADC linked to auristatin (MMAE) is prepared through a MC-vc-PAB linker. It is confirmed that such an ADC exhibits the desired cytotoxicity.
[0323] Chimeric Antigen Receptor (CAR)
[0324] Another aspect of the present invention relates to a chimeric antigen receptor, characterized in that the chimeric antigen receptor (CAR) comprises: an extracellular domain comprising an antigen binding site, a transmembrane domain and an intracellular signaling domain, and the antigen binding site of the extracellular domain is the scFv of the antibody.
[0325] Chimeric antigen receptor (CAR) is a synthetic structure designed to induce an immune response to a target antigen and cells expressing the antigen. CAR comprises an extracellular domain, a transmembrane domain, and an intracellular signaling domain. Genes encoding receptors that recognize cancer cell surface antigens specifically expressed on the surface of cancer cells can be introduced into immune cells to kill cancer cells. By comprising immune cells that bind to receptors specifically expressed in cancer cells, only cancer cells can be targeted and an immune response can be induced. The CAR comprises the scFv of the anti-FGFR3 antibody of the present invention as an antigen recognition site of the extracellular domain.
[0326] The first generation CAR includes: an extracellular domain including an antigen recognition site specifically expressed in cancer cells, a transmembrane domain, and an intracellular signaling domain. As a signaling domain, only CD3ζ is used, but the therapeutic effect on cancer is minimal and there is a problem of short duration. This first generation CAR is specifically described in U.S. Patent No. 6319494 and is introduced into the present invention as a reference.
[0327] In order to improve the responsiveness to immune cells, a second generation CAR combining a costimulatory domain (CD28 or CD137 / 4-1BB) and CD3ζ is prepared, and the number of immune cells containing CAR remaining in the body is significantly increased compared with the first generation CAR. The second generation CAR uses a costimulatory domain, while more than two costimulatory domains are used in the third generation CAR. In order to achieve the amplification and persistence of immune cells containing CAR in vivo, the costimulatory domain can be combined with 4-1BB, CD28 or OX40, etc. The second generation CAR is specifically recorded in U.S. Patent No. 7741465, No. 7446190 or No. 9212229, and the third generation CAR is specifically recorded in U.S. Patent No. 8822647, and is introduced into the present invention as a reference.
[0328] The fourth generation CAR includes additional genes encoding cytokines such as IL-12 or IL-15, so that CAR-based immune proteins of cytokines can be further expressed, and the fifth generation CAR further includes interleukin receptor chains, for example, IL-2Rβ, in order to enhance immune cells. The fourth generation CAR is specifically described in U.S. Patent No. 10316102, and the fifth generation CAR is specifically described in U.S. Patent No. 10336810, and is introduced into the present invention as a reference.
[0329] In one embodiment, the antigen binding site of the extracellular domain is an scFv of an antibody. The VH and VL domains of the scFv comprising the VH and VL domains of the antibody can be connected by a linker. The heavy chain variable region can be connected to the light chain variable region by a linker, the heavy chain variable region comprising one or more amino acid sequences selected from SEQ ID NO.133 to SEQ ID NO.157, SEQ ID NO.203 to SEQ ID NO.215, and the light chain variable region comprising one or more amino acid sequences selected from SEQ ID NO.158 to SEQ ID NO.182, SEQ ID NO.216 to SEQ ID NO.219.
[0330] The linker may be a peptide linker and may have a length of about 10-25 aa. For example, it may comprise hydrophilic amino acids such as glycine and / or serine.
[0331] The linker may for example comprise (GS) n 、(GGS) n 、(GSGGS) n or (G n S) m (n, m are 1 to 10, respectively), but the linker can be, for example, (G n S) m (n and m are 1 to 10, respectively). Specifically, the linker may comprise GGGGS, for example, GGGGSGGGGSGGGGS of SEQ ID NO. 185 repeated three times.
[0332] The transmembrane domain can be derived from a natural or synthetic supply source. When the supply source is natural, the domain can be derived from any membrane-bound protein or transmembrane protein. The transmembrane domain can include α, β or ζ chains of T-cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, ICOS. When synthesizing the transmembrane domain, hydrophobic residues such as leucine and valine may be included, or peptides containing phenylalanine, tryptophan and valine may be included at each end. A short oligonucleotide or polypeptide linker of 2-10 amino acids in length can form a bond between the transmembrane domain and the cytoplasmic signaling domain of CAR. Glycine-serine peptides can be used as linkers.
[0333] The signaling domain can induce activation of the normal effector function of the immune cell in which the CAR is located. For example, cell lysis activation or auxiliary activation can be induced by the secretion of cytokines. The signaling domain transduces effector function signals and thus can include a fragment of a segment of a sufficient intracellular signaling domain.
[0334] The signal transduction domain may include a cytoplasm of a T cell receptor (TCR) and a co-receptor that act synergistically to initiate signal transduction after intervening an antigen receptor.
[0335] And it is known that the signal formed by a single TCR is not enough to fully activate T cells and requires a costimulatory signal. Therefore, the situation of starting antigen-dependent primary activation by TCR and acting in an antigen-dependent manner to provide a secondary or costimulatory signal may involve T cell activation. The primary cytoplasm signaling sequence regulates the primary activation of the TCR complex in a stimulating manner or in an inhibitory manner. The primary cytoplasm signaling sequence acting in a stimulating manner can contain an activation motif based on the tyrosine of an immunoreceptor or a signaling motif known as ITAM. The example of ITAM containing a primary cytoplasm signaling sequence can include TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b and CD66d.
[0336] Depending on the situation, the cytoplasmic domain of CAR may include a CD3ζ chain portion and a costimulatory signaling region. The costimulatory signaling region refers to a portion of a CAR that includes an intracellular domain of a costimulatory molecule. For example, it may include a ligand that specifically binds to CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83. The cytoplasmic signaling sequence in the cytoplasmic signaling portion of CAR can be connected by 2-10 amino acids, for example, by a peptide linker comprising glycine-serine.
[0337] Another aspect of the present invention relates to an immune cell into which the chimeric antigen receptor (CAR) is introduced.
[0338] The immune cells can induce the desired cancer treatment effect by inducing immunity, for example, can be selected from T cells, NK cells, cytokine-induced killer cells (CIK), activated cytotoxic T lymphocytes (CTL), macrophages, tumor-infiltrating T cells (tumor-infiltrating lymphocytes, TIL), dendritic cells, but are not limited thereto.
[0339] Depending on the situation, a chimeric antigen receptor (CAR) comprising an antigen binding site for scFv of an antibody other than the anti-FGFR3 antibody as an extracellular domain may be further introduced.
[0340] The antibody other than the anti-FGFR3 antibody can be an antibody or an antigen-binding fragment thereof that targets, for example, one or more selected from PD-1, PD-L1, BTLA, CTLA-4, VISTA, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
[0341] Vesicles and Exosomes
[0342] Another aspect of the present invention relates to a vesicle, wherein the vesicle is an antibody or an antigen-binding fragment thereof exposed on the outside of the vesicle or present in the inside of the vesicle.
[0343] The vesicle is a vesicle that can directly introduce the target protein into the cell through the cell membrane, and comprises the cell membrane and the antibody or antigen-binding fragment thereof of the present invention.
[0344] The vesicle of the present invention may be in the form of a cell membrane and a target agent to be delivered. Examples of such vesicles are specifically described in U.S. Patent Publication No. 2018 / 0177725 and can be introduced into the present invention as a reference.
[0345] The vesicles may, for example, have an average diameter of 40-500 nm, specifically 100-300 nm, 80-200 nm or 100 nm. The vesicles may, for example, be about 100 nm, 200 nm, 300 nm, 400 nm or 500 nm.
[0346] The vesicle may not contain other intracellular small organs such as mitochondria, lysosomes or Golgi bodies, in addition to the cell membrane and the antibody or antigen-binding fragment thereof of the present invention.
[0347] The vesicle may include a membrane to be divided into an inside and an outside, and the antibody or antigen-binding fragment thereof may be present in the membrane and exposed to the outside, or exposed to the inside, or separated from the membrane and present in the inside of the vesicle.
[0348] The membrane of the vesicle may vary depending on the target of the antibody or antigen-binding fragment thereof to be used. For example, the membrane of the cancer cell may be used to deliver the antibody or antigen-binding fragment thereof to FGFR3-expressing cancer cells, but is not limited thereto.
[0349] The cancer cells may, for example, include cancer cells that induce Hodgkin's lymphoma, non-Hodgkin's lymphoma (e.g., B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma or acute lymphocytic leukemia.
[0350] In addition, it can include cancer cells that induce solid tumors, such as ovarian cancer, colorectal cancer, gastric cancer, testicular cancer, perianal cancer, uterine cancer, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, Kaposi's sarcoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular malignant melanoma, uterine cancer, brain stem glioma, pituitary adenocarcinoma, epidermoid carcinoma, cervical squamous cell carcinoma, fallopian tube cancer, endometrial cancer, vaginal cancer, soft tissue sarcoma, urethral cancer, vulvar cancer, penile cancer, bladder cancer, kidney cancer or ureter cancer, renal pelvis cancer, spinal cord tumors, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, and metastatic cancer cells of the above cancers.
[0351] Further, for example, cancer cells inducing glioblastoma, lung cancer, bladder cancer, oral cancer, head and neck squamous cell carcinoma, gallbladder cancer, or cervical cancer may be included.
[0352] The vesicles may be, for example, exosomes, which are small vesicles with a membrane structure of 50-200 nm that are used for intercellular signal transduction and contain proteins, DNA, RNA, etc. and are secreted outside the cells.
[0353] Exosomes contain various proteins, DNA, RNA, etc. in cells. Substances contained in such exosomes and secreted outside cells are reintroduced into other cells through fusion with cell membranes or endocytosis, thereby also acting as intercellular communicators. In addition, substances contained in such exosomes and secreted outside cells can be analyzed for diagnosis of specific diseases.
[0354] According to the present invention, the antibody or antigen-binding fragment thereof is exposed to the outside of the exosome or exists in the inside thereof. The exosome has a membrane structure and can be divided into an inside and an outside, and the antibody or antigen-binding fragment thereof is present in the exosome membrane, so it can be exposed to the outside or exposed to the inside or separated from the membrane and exist in the exosome.
[0355] The exosomes may be artificial exosomes derived from immune cells / stem cells having various targeting properties, loaded with specific drugs, targeted and delivered to desired diseased tissues in the human body, thereby significantly reducing side effects on other tissues, and maximizing the therapeutic efficacy with a small amount of drugs, for example, as specifically described in International Publication No. WO2011 / 002239, and introduced into the present invention as a reference.
[0356] When the antibody or antigen-binding fragment thereof is present in the exosome membrane and is exposed to the outside or to the inside, the antibody or antigen-binding fragment thereof can be expressed in the form of being fused with an exosome-specific marker, thereby capturing the antibody or antigen-binding fragment thereof inside the exosome. When the exosome membrane is fused with the cell membrane of a cell expressing FGFR3, the antibody or antigen-binding fragment thereof can be delivered to the cell.
[0357] The antibody or its antigen-binding fragment may be displayed on the surface of the exosomes. For example, a prostaglandin F2 receptor negative regulator (PTGFRN) protein may be expressed on the surface of the exosomes, and other target proteins may be fused to the PTGFRN protein. Such exosomes are specifically described in International Publication Nos. WO2014 / 076137 and WO2018 / 09119, etc., and are introduced into the present invention as a reference.
[0358] In the case of exosomes containing the antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof can be prepared by temporarily binding the antibody or antigen-binding fragment thereof to the marker protein using a photospecific binding protein. The target protein can be captured in the exosome without being bound to the membrane. When the exosome is delivered to the cell by internalization, the exosome is degraded, so that the antibody or antigen-binding fragment thereof can be delivered to the cell.
[0359] The process of making the antibody or its antigen-binding fragment present inside is specifically described in International Patent Publication Nos. WO2016 / 178532 and WO2018 / 062973, etc., and is introduced into the present invention as a reference.
[0360] For example, CIBN and CRY2 as light-specific binding proteins can be used. Specifically, genes encoding these fusion proteins can be introduced into exosome-producing cells, so that the CIBN is expressed in a form fused with CD9 as one of the marker proteins and the CRY2 is expressed in a form fused with the antibody or its antigen-binding fragment. The CIBN-CD9 fusion protein expressed in the exosome-producing cells is contained in the exosomes due to CD9. At this time, when the cells are irradiated with blue LED light, the CRY2 domain of the target protein-CRY2 fusion protein expressed in the exosome-producing cells binds to the CIBN domain fused with CD9, thereby forming a reversibly induced fusion protein in the form of target protein-CRY2-CIBN-CD9, and due to CD9, the fusion protein as described above can be contained inside the exosomes. After the exosomes containing the target protein are produced in this way, when the blue LED light is no longer irradiated, the CIBN-CRY2 binding is released, so that the target protein can be contained inside the exosomes in a state that is not bound to the cell membrane of the exosomes.
[0361] Therapeutic compositions
[0362] Another aspect of the present invention relates to a composition for treating cancer, inflammation or immune disease, comprising: the antibody or its antigen-binding fragment, a bispecific antibody or a multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate comprising the antibody or its antigen-binding fragment, a chimeric antigen receptor comprising the antibody or its antigen-binding fragment, or an immune cell comprising the chimeric antigen receptor.
[0363] The present invention may be, for example, a pharmaceutical composition for preventing or treating cancer, comprising: (a) an antibody or antigen-binding fragment thereof to FGFR3 of the present invention, a bispecific antibody or multispecific antibody comprising the antibody or antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof, a chimeric antigen receptor comprising the antibody or antigen-binding fragment thereof, or an immune cell comprising the chimeric antigen receptor, in an effective amount of a drug; and (b) a pharmaceutically acceptable carrier. The present invention may also be a method for preventing or treating cancer, comprising administering the antibody or antigen-binding fragment thereof to FGFR3 of the present invention, a bispecific antibody or multispecific antibody comprising the antibody or antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof, a chimeric antigen receptor comprising the antibody or antigen-binding fragment thereof, or an immune cell comprising the chimeric antigen receptor to a cancer patient.
[0364] "Prevention" refers to all actions to inhibit the growth or delay the progression of cancer by administering the composition of the present invention, and "treatment" refers to the inhibition of cancer development, the alleviation of tumors, or the elimination of cancer.
[0365] The cancer includes, for example, Hodgkin's lymphoma, non-Hodgkin's lymphoma (e.g., B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, border zone B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma or acute lymphocytic leukemia.
[0366] The cancers include, for example, ovarian cancer, colorectal cancer, gastric cancer, testicular cancer, perianal cancer, uterine cancer, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, Kaposi's sarcoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, brain stem glioma, pituitary adenocarcinoma, epidermoid carcinoma, cervical squamous cell carcinoma, fallopian tube cancer, endometrial cancer, vaginal cancer, soft tissue sarcoma, urethral cancer, vulvar cancer, penile cancer, bladder cancer, kidney cancer or ureter cancer, renal pelvis cancer, spinal cord tumors, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of the cancers, or combinations of the cancers.
[0367] The cancer may be, for example, glioblastoma, lung cancer, bladder cancer, oral cancer, squamous cell carcinoma of the head and neck, gallbladder cancer, or cervical cancer. In particular, in the case of glioblastoma, the antibody or its antigen-binding fragment needs to pass through the blood-brain barrier, which is a barrier formed by tight junctions in the capillary endothelial cell membrane of the brain between the brain and the spine and its surrounding circulatory system. In order to pass through the BBB, it can be used in connection with a transporter. In order to deliver drugs through the BBB, there are methods such as bradykinin or methods such as high-intensity focused ultrasound (HIFU) to destroy the osmotic pressure of the BBB. In addition, the use of delivery systems such as intrinsic glucose and amino acid transporters, insulin or transferrin receptor-mediated transcytosis in cells or methods that block the active efflux delivery of glycoproteins (efflux transporters) can be included.
[0368] The inflammation may be, for example, chronic obstructive pulmonary disease, celiac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, oral ulcers, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), enteritis or allergic reaction, urethritis, cystitis, vaginitis, proctoanitis, eosinophilic gastroenteritis or rheumatoid arthritis, but is not limited thereto.
[0369] The immune disease may be, for example, acquired immunodeficiency disease, autoimmune disease, systemic lupus erythematosus, scleroderma, Sjögren's syndrome, polymyositis and dermatomyositis, rheumatoid polymyalgia, temporal arteritis, polyarteritis nodosa or Behcet's syndrome.
[0370] The pharmaceutically acceptable carrier included in the composition of the present invention is a carrier commonly used during formulation, and the carrier includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate and mineral oil, but is not limited thereto. The composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. in addition to the ingredients.
[0371] The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenterally administered, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, nasal administration, pulmonary administration and rectal administration.
[0372] When orally administered, proteins or peptides are digested, so oral compositions should be formulated to coat the active agent or to prevent degradation in the stomach. In addition, pharmaceutical compositions can be administered by any device that allows the active substance to move to target cells.
[0373] The suitable dosage of the composition of the present invention is different according to factors such as formulation method, mode of administration, age, weight, sex, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity of the patient, and a skilled doctor can easily determine the dosage effective for the desired treatment or prevention and prescribe it. For example, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-100 mg / kg. The term "pharmaceutically effective amount" in this specification refers to the amount sufficient for preventing or treating cancer or autoimmune disease.
[0374] The pharmaceutical composition of the present invention can be formulated using pharmaceutically acceptable carriers and / or excipients according to methods that can be easily implemented by those skilled in the art to which the present invention belongs, and prepared in unit dosage form or by introducing into a multi-dose container. In this case, the dosage form can be a solution, suspension or emulsion in an oily or aqueous medium, or can also be an extract, powder, suppository, powder, granule, tablet or capsule, and can further contain a dispersant or stabilizer.
[0375] Combination therapy
[0376] The present invention relates to a combination therapeutic composition comprising immune cells and a drug other than an anti-FGFR3 antibody.
[0377] In one embodiment, the drug other than an anti-FGFR3 antibody may comprise a chemotherapeutic agent or an antibody other than an anti-FGFR3 antibody.
[0378] The drug can be selected from maytansine compounds, auristatins (including MMAE, MMAF), aminopterin, actinomycin, bleomycin, talithromycin, camptothecin, N8-acetyl spermidine, 1-(2-chloroethyl)-1,2-dimethylsulfonyl hydrazide, esperamicin, etoposide, 6-mercaptopurine, dolestacin, trichothecenes, calicheamicin, taxol, taxane, paclitaxel, docetaxel, methotrexate, vincristine, vinblastine, doxorubicin, melphalan, mitomycin A, mitomycin C, chlorambucil, duocarbinase, L-asparaginase, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, methyl benzylhydrazine, topotecan, nitrogen mustard, cyclophosphamide, etoposide, 5-fluorouracil, dichloroethyl nitrosourea (CNU), irinotecan, camptothecin, bleomycin, idarubicin, daunomycin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinorelbine, chlorambucil, melphalan, carmustine, lomustine, busulfan, trioxalic acid, dacarbazine, etoposide, teniposide, topotecan, 9-aminocamptothecin, clenatol, mitomycin C, trimetrexate, mycophenolic acid, thiazolidinone, ribavirin, 5-ethynyl-1-β-D-ribofuranosyl imidazole-4-carboxamide (EICAR), hydroxyurea sulfate, deferoxamine, floxuridine, doxifluridine, raltitrexed, cytarabine (arabinoside) C), cytosine arabinoside, fludarabine, tamoxifen, raloxifene, megestrol acetate, goserelin, leuprolide acetate, flutamide, bicalutamide, EB1089, CB1093, KH1060, verteporfin, phthalocyanine, photosensitizer Pe4, demethoxy-hypocrellin A, interferon-α, interferon-γ, tumor necrosis factor, gemcitabine, velcade, remide, tyramide, lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, actinomycin D, dactinomycin, bleomycin A2, bleomycin B2, peplomycin, epirubicin, pirarubicin, doxycycline, mitoxantrone, verapamil, and one or more of thapsigargin, nuclease, and toxins derived from bacteria, animals, or plants.
[0379] In one embodiment, the antibody other than the anti-FGFR3 antibody can be, for example, an antibody targeting one or more selected from PD-1, PD-L1, BTLA, CTLA-4, VISTA, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO, or an antigen-binding fragment thereof.
[0380] The present invention relates to a combination therapy composition comprising an antibody or an antigen-binding fragment thereof, and one or more selected from (i) an immune cell; (ii) an immune cell comprising an antigen receptor (CAR) comprising an scFv for an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) an immune checkpoint inhibitor.
[0381] In addition, the present invention relates to a combination therapy composition comprising the immune cell-engaged bispecific antibody or multispecific antibody, and one or more selected from (i) immune cells; (ii) immune cells comprising an antigen receptor (CAR), wherein the antigen receptor comprises an scFv fragment for an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) immune checkpoint inhibitors.
[0382] The immune cells induce immunotherapy, for example, can induce immunity and induce the desired cancer treatment effect. The immune cells can be selected from, for example, T cells, NK cells, cytokine-induced killer cells (CIK), activated cytotoxic T lymphocytes (CTL), macrophages, tumor-infiltrating T cells (tumor-infiltrating lymphocytes, TIL), dendritic cells, but are not limited to these.
[0383] The antibody other than the anti-FGFR3 antibody is an antibody targeting a target other than FGFR3, for example, it may be an antibody or an antigen-binding fragment thereof that binds to LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1 or MARCO, but is not limited thereto.
[0384] The present invention relates to a combination therapy composition comprising an antibody or an antigen-binding fragment thereof, and one or more selected from (i) an immune cell; (ii) an immune cell comprising an antigen receptor (CAR) comprising an scFv for an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) an immune checkpoint inhibitor.
[0385] In addition, the present invention relates to a combination therapy composition comprising the immune cell-engaged bispecific antibody or multispecific antibody, and one or more selected from (i) immune cells; (ii) immune cells comprising an antigen receptor (CAR) comprising an scFv fragment for an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) immune checkpoint inhibitors.
[0386] The immune cells induce immunotherapy, for example, can induce immunity and induce the desired cancer treatment effect. The immune cells can be selected from, for example, T cells, NK cells, cytokine-induced killer cells (CIK), activated cytotoxic T lymphocytes (CTL), macrophages, tumor-infiltrating T cells (tumor-infiltrating lymphocytes, TIL), dendritic cells, but are not limited to these.
[0387] The antibody other than the anti-FGFR3 antibody is an antibody targeting a target other than FGFR3, for example, it can be an antibody or an antigen-binding fragment thereof that binds to LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1 or MARCO, but is not limited thereto.
[0388] The immune checkpoint inhibitor refers to the site where antigen presenting cells (antigen presenting cell, APC) and immune cells (such as T cells) meet, and refers to a preparation that can block T cell inhibition signals to induce T cell activation. The immune checkpoint inhibitor can, for example, be a drug targeting PD-1, PD-L1, BTLA, CTLA-4, VISTA, LAG3, TIM3, CD137 (4-1BB), CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200 or CD200R, but is not limited thereto.
[0389] The first component and the second component of the combined administration object can be administered simultaneously. In addition, the first component and the second component of the combined administration object can also be administered separately at a certain time interval. The second component can be administered separately before or after the first component is administered to the combined administration object.
[0390] Companion diagnostics (CDx)
[0391] Companion diagnostics is a type of molecular diagnostic technology used to predict a patient's responsiveness to a specific drug treatment. In the application of a drug, screening criteria for the intended patients are proposed and the specificity and sensitivity of diagnostic, prognostic and predictive biomarkers that meet the criteria are considered, so that criteria for treating patients with appropriate drugs can be proposed.
[0392] In the case of anticancer drugs, they are very effective for patients who show response, but the rate of patients who show response is low, so it is very important to screen out patients who show effect. Patients who show response to anticancer drugs can be screened through companion diagnostics, thereby improving the treatment efficiency of patients.
[0393] Another aspect of the present invention relates to a composition for treating cancer, which is used to treat cancer confirmed to be amplified, mutated, overexpressed or constitutively activated fusion gene of FGFR3 and TACC3, and comprises: the antibody or its antigen-binding fragment, a bispecific antibody or multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate, a chimeric antigen receptor or an immune cell comprising the chimeric antigen receptor.
[0394] The present invention also relates to a method for treating cancer, comprising: administering the antibody or its antigen-binding fragment, a bispecific antibody or multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate, a chimeric antigen receptor, or an immune cell comprising the chimeric antigen receptor, when amplification of the fusion gene of FGFR3 and TACC3, mutation of the fusion gene, overexpression of the fusion gene, or constant expression (constitutive activation) of the fusion gene is confirmed in a sample derived from a patient.
[0395] The sample refers to a biological object obtained from a patient's tissue or body fluid. The supply source of the tissue sample can be: solid tissue such as from frozen and / or preserved organs, tissue samples, biopsies or extracts; blood or any blood components (e.g., serum, plasma); bone marrow or any bone marrow components; body fluids such as urine, cerebrospinal fluid, whole blood, plasma and serum. The sample can include non-cellular separation (e.g., urine, plasma, serum or other non-cellular body fluids). The sample can include body fluids, such as blood (e.g., whole blood). Specifically, the sample can be a whole blood sample, a whole bone marrow sample, a whole peripheral blood sample or a whole tumor sample obtained from a patient. The "whole" sample refers to a sample that does not actually have a component (e.g., cell) removed or separated from the sample. The sample, for example, a blood sample can be diluted before use (e.g., by a physiologically compatible buffer or culture medium). In another specific embodiment, a "whole" sample, such as a whole tissue sample or a whole tumor sample, substantially maintains a microenvironment derived from the tissue of origin, such as substantially maintaining the structure of a tumor or immune microenvironment. Specifically, a sample, such as a tumor sample, can be processed (eg, ground, minced, mixed, pulverized, etc.) into smaller pieces, and can be diluted (eg, with a physiologically compatible buffer or culture medium).
[0396] The expression confirmation of the gene is the process of confirming whether the gene exists and the degree of expression, which can be carried out by polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), competitive reverse transcription polymerase chain reaction (Competitive RT-PCR), real-time reverse transcription polymerase chain reaction (Real-time RT-PCR), RNase protection assay (RPA), Northern blotting, DNA chip, etc.
[0397] Polymerase chain reaction (PCR) can be performed by gene amplification reaction using primers. It can be performed by multiplex PCR, real-time PCR, differential display PCR (DD-PCR), rapid amplification of cDNA ends (RACE), inverse polymerase chain reaction (IPCR), vectorette PCR and thermal asymmetric interlaced PCR (TAIL-PCR).
[0398] It is also possible to detect whether a protein is expressed by a gene encoding a protein. This is the process of confirming the presence and degree of expression of a protein expressed from the gene. The amount of the protein can be confirmed using antibodies, oligopeptides, ligands, peptide nucleic acids (PNA) or aptamers that specifically bind to the protein.
[0399] The analysis methods for this purpose may include methods utilizing protein immunoblotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, flow cytometry (Fluorescence Activated Cell Sorter (FACS)), protein chip, and the like.
[0400] Example
[0401] The present invention will be described in more detail below by way of examples. It will be apparent to those skilled in the art that these examples are only used to illustrate the present invention and are not to be construed as limiting the scope of the present invention to these examples.
[0402] Example 1: Screening of phage antibodies specific to FGFR3, cell panning (phage display technology)
[0403] Our research group used a synthetic scFv phage library {(1) Bai, Xuelian & Kim, Jihye & Kang, Seungmin & Kim, Wankyu & Shim, Hyunbo. (2015). A Novel Human scFv Library with Non-Combinatorial Synthetic CDR Diversity. PloSone. 10.e0141045.10.1371 / journal.pone.0141045., (2) Yang, Hye & Kang, Kyung & TCW, Julia & Shim, Hyunbo. (2009). Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Molecules andcells.27.225-35.10.1007 / s10059-009-0028-9.}, a cell panning method for screening antibodies with cell internalization function was performed. FGFR3 overexpression cells (682T) and FGFR3 low expression cells (626T) were verified by RPKM analysis value and protein expression confirmed by protein immunoblotting, and the corresponding cells were selected. FGFR3 low expression cells were treated with pre-recovered phage library stock (phage library stock), reacted at 4 degrees for 1 hour, and then only the supernatant was recovered by a centrifuge and the pre-prepared FGFR3 overexpression cells were treated, and reacted at 4 degrees for 1 hour. Afterwards, non-specific phage (phage) was removed by culture medium and cultured at 37 degrees for 30 minutes to recover the antibody for cell internalization. As for the recovery method, the non-specific cell surface-bound phages are washed and removed by low pH buffer, and then the cells are dissolved by lysis buffer to recover the antibodies that have cell internalization function through FGFR3 specific binding inside the cells, and infect E. coli. The infected E. coli is amplified again, and the same cell selection method is further performed 2 times, so that a total of 3 cell selections are performed and then ELISA screening is performed to screen FGFR3-specific antibodies. The corresponding experimental schematic diagram is shown in [ Figure 1a ] as shown.
[0404] Example 2: Screening of phage antibodies specific to FGFR3, antigen fixation panning (phage display technology)
[0405] Using the same phage library, the commonly used immobilized antigen panning was performed. FGFR3-IIIc / Fc antigen and negative / Fc antigen were coated on an immune tube at 3ug / ml (overnight, 4 degrees), and the pre-recovered phage library stock solution was first reacted in a pre-blocked negative / Fc antigen at room temperature for 1 hour. Afterwards, the supernatant was recovered and reacted in a pre-blocked FGFR3-IIIc / Fc tube at room temperature for 1 hour. Afterwards, the non-specific phages were removed by washing with PBST, and the phages specific to the FGFR3-IIIc / Fc antigen were recovered by low pH buffer. After the phage was used to infect E. coli and undergo amplification, the same panning method was further performed three times, and a total of four bio-pannings were performed before ELISA screening to screen FGFR3-specific antibodies. The corresponding experimental schematic diagram is shown in [ Figure 1b ] as shown.
[0406] Example 3: Screening of phage antibodies specific to FGFR3, magnetic bead panning; semi-automated panning (phage display technology)
[0407] Semi-automated bio-panning is performed using the same phage library. This method is based on magnetic beads based panning, which is a method of treating phages with biotinylated target antigens and then washing and recovering antigen-specific phages after the binding process using a chromatographic column or a magnetic chamber. Figure 1cThe inventors introduced this series of processes into a semi-automated system. In the Kingfisher Flex (Thermo Scientific) device, the phage library stock solution, biotinylated FGFR3-IIIc / Fc antigen, streptavidin-M280 dynabeads, 0.1% PBST washing buffer, elution buffer and other reagents were distributed in 24 deep wells of the Kingfisher Flex and the pre-made software protocol (BindIt TM Software) for bio-panning Figure 1d The bio-panning was repeated 3-4 times to amplify and recover phages that specifically bind to the FGFR3 antigen. The phages were used for ELISA screening to screen for FGFR3-specific antibodies.
[0408] Example 4: Antibody screening based on affinity ELISA
[0409] The product of each bio-panning method is the state of E. coli host cells (TG1), which are ensured by smearing these E. coli host cells as single colonies on agar LB / Ampicillin medium, and randomly inoculated into SB / Ampicillin medium for culture (3 hours, 37 degrees). After that, in order to induce scFv-pIII protein, each well is treated with IPTG at a final concentration of 1mM and cultured overnight at 30 degrees. The next day, the supernatant of the cultured 96-well plate was removed by centrifugation, and only E. coli was recovered, treated with 1x TES solution (20% w / v sucrose, 50mM Tris, 1mM EDTA, pH 8.0), suspended at 4 degrees for more than 1 hour, and then further treated with 0.2x TES solution and suspended for more than 2 hours, thereby extracting scFv-pIII protein present in the periplasmic part of E. coli cells. The day before, FGFR3 recombinant protein and negative recombinant protein were pre-coated with 1ug / ml in 96-well plates overnight and at 4 degrees, and each plate was treated with extracted scFv-pIII, and reacted at room temperature for 1 hour. After the reaction, PBST was used to clean, and anti-HA antibody with HRP was used for 1 hour, and the color reaction (TMB substrate) was induced again through the cleaning process to measure the OD value (450nm). The OD ratio of FGFR3 recombinant protein / negative recombinant protein was calculated to screen FGFR3 specific scFv-pIII clones. With regard to the screening criteria, it was converted to a relative ratio of (positive / negative), and antibody sequence analysis was performed on clones with a value of more than 2.
[0410] In the case of biopanning using patient-derived cells, 564 single clones of the completed output phage were screened by ELISA, of which 10 positive clones were identified [ Figure 2a In the case of antigen-immobilized biopanning, 658 clones were screened by ELISA (a total of 1316) in two independent experiments, of which 328 positive clones were identified [ Figure 2b ]. After completing the magnetic-based semi-automated biopanning, 376 clones were screened by ELISA and 26 positive clones were identified [ Figure 2c ].
[0411] Example 5: Antibody sequence analysis
[0412] Affinity ELISA screening analysis results, OD ratio (FGFR3 antigen / negative antigen) is more than 2 clones for antibody sequence analysis. The clones screened in a 14ml round tube were cultured in LB / ampicillin medium with a phagemid vector (phagemid vector) of the Escherichia coli, and then DNA preparation (prep) (mini-prep), thereby extracting plasmid DNA. The extracted DNA was analyzed by using a primer that matches the part of the scFv sequence with a phagemid vector.
[0413] According to the sequence analysis results of each method, two antibody intrinsic sequences were analyzed during cell panning, 26 antibody unique sequences were analyzed during antigen fixation panning, and 8 antibody unique sequences were analyzed during semi-automatic panning. On this basis, the results of repeated ELISA in scFv format were performed on each corresponding clone, and finally 25 clones showing FGFR3 specific binding ability were identified, and the sequences of heavy and light chains were analyzed.
[0414] [Table 1]
[0415]
[0416]
[0417] [Table 2]
[0418]
[0419]
[0420]
[0421] [Table 3]
[0422]
[0423] [Table 4]
[0424]
[0425]
[0426]
[0427] Example 6: Conversion of scFv antibody fragments to IgG and antibody production
[0428] Based on the FGFR3 antibody sequence confirmed by sequence analysis, the heavy chain production vector and light chain production vector owned by our research group were cloned to construct an IgG production vector. Based on the constructed production vector, the FGFR3 antibody was produced using the mammalian protein expression system (Expi293F), and the MabSelect SuRe affinity chromatography based on the AKTA prime plus device was used. TM The high-purity antibody was recovered and purified. The high-purity sample characteristics ( Figure 3a , Figure 3b ).
[0429] Example 7: Evaluation of antigen binding ability of FGFR3 antibodies; ELISA
[0430] In order to confirm the binding ability of the produced antibody (IgG) to FGFR3 antigen, affinity ELISA was performed. The FGFR3 antigen was coated on a 96-well plate (4 degrees, overnight) with 1-2ug / ml, and then blocked with 3% skim milk (skim milk) (PBS) (normal temperature, 1 hour). Afterwards, duplicate and triplicate were processed with the antibody samples diluted in advance, and reacted at room temperature for 1 hour. Afterwards, PBST was used to clean 2-3 times, and then the anti-human Fab antibody bound to HRP was diluted in skim milk and processed (normal temperature, 1 hour), and then washed with PBST again and a color reaction (TMB substrate) was performed. Afterwards, the value measured with an OD of 450nm was confirmed.
[0431] The same method was used to confirm the expression of human FGFR3 IIIb (1264-FR-050, R&D), IIIc (766-FR-050, R&D), mouse FGFR3 (9089-FR, R&D), and monkey FGFR3 (90313-C02H, Sinobiological) antigens.
[0432] Confirm the binding capacity of each antibody at each concentration ( Figures 4a to 4d ), OD values were converted to relative values and plotted. KD values were calculated based on EC50 (Table 5a to Table 5d).
[0433] [Table 5a] [rhFGFR3-IIIc specific binding ability: EC determined by direct binding ELISA 50 (EC 50 determined by direct-binding ELISA)]
[0434]
[0435] [Table 5b] [rhFGFR3-IIIb specific binding ability: EC determined by direct binding ELISA 50 ]
[0436]
[0437] [Table 5c] [rmFGFR3-IIIc specific binding ability: EC determined by direct binding ELISA 50 ]
[0438]
[0439] [Table 5d] [rcynoFGFR3-IIIc specific binding ability: EC50 determined by direct binding ELISA]
[0440]
[0441] Example 8: Evaluation of Antigen Binding Ability of FGFR3 Antibodies; SPR
[0442] In order to evaluate the binding ability of produced antibodies (IgG) to FGFR3 subtypes and subfamily, SPR analysis was performed. The affinity measurement based on SRP of FGFR3 antibody candidate group to FGFR3 antigen uses Biacore-T200 equipment. By amine coupling, the antigen identical with the antigen described in ELISA binding ability is directly fixed on CM5 biosensor chip, and reaches about 300RU. With a flow rate of 30ug / minute, 2 times of diluent (25 degrees) are injected successively and continuously during the binding time of 180 seconds with about 20nM concentration, and then the separation step is carried out for 180 seconds with the same flow rate. Inject 10mM glycine-HCl as buffer between each injection, so as to regenerate CM5 biosensor chip. Use one-to-one Langmuir binding model to calculate binding rate and dissociation rate. The equilibrium dissociation constant (KD) is calculated with the ratio of Koff / Kon ( Figure 5 , Table 6).
[0443] [Table 6]
[0444]
[0445] ND:not defined
[0446] NB: non-binding
[0447] Example 9: Confirmation of FGFR3 protein expression; Western blotting, FACS analysis
[0448] In order to perform cell surface binding and other assays on the FGFR3 antibodies discovered in the present invention to select FGFR3 overexpressing cells, protein immunoblotting and FACS analysis were performed. Patient-derived cells and cancer cell lines were selected as mRNA expression levels (RPKM), and each cell was subcultured to ensure a certain number of cells, and then in the case of protein immunoblotting, lysates were prepared for verification, and in the case of FACS analysis, cell surface FGFR3 expression was directly confirmed. First, in the case of protein immunoblotting, cOmplete TM Dissolve-M(cOmplete TM Lysis-M) (Roche) was used to lyse each cell, and then Bradford protein quantitative analysis was performed, and 20ug of the lysate was subjected to protein immunoblotting. Total FGFR3 (sc-13121, Santa Cruz) and β-actin were confirmed to compare the relative expression of FGFR3 protein between cell lines. In the case of FACS, each cell cultured was distributed at 3.0-5.0E+05 cells / tube, and FGFR3-PE direct antibody (FAB766P, R&D) was reacted for 1 hour at 4 degrees, washed 2-3 times, and then analyzed with BD FACSAria TM Analysis was performed using the ELISA kit (BD Biosciences).
[0449] Western blot results showed that 682T and 526T patient-derived cells were identified as FGFR3 overexpressing cells. On the other hand, 626T and 559T were identified as having almost no FGFR3 expression. The same was also verified in the FACS results. In particular, it is believed that 682T cells have a very high FGFR3 expression level on the cell surface ( Figure 6a ).
[0450] Example 10: Validation of FGFR3-TACC3 fusion; RT-PCR
[0451] FGFR3 appears in various cancers in the form of overexpression, amplification, mutation, fusion. Among them, it is reported that the prognosis of bladder cancer and brain tumors of patients with FGFR3-TACC3 fusion is not good. Therefore, the therapeutic agent for this has the possibility of overcoming unmet medical needs. Therefore, the present invention is based on the FGFR3-TACC3 fusion analysis of cells derived from patients to be grouped, and RT-PCR technology is used to confirm it. By subculturing, the cells GBM15-682T, GBM14-526T, BT16-1154T, GBM14-606T, NS10-783T derived from patients are propagated and then recovered a certain amount, and RNA is extracted using RNeasy Mini Kit (Mini Kit) (Qiagen). The extracted RNA is unstable, so RT-PCR (SuperscriptIV reverse transcriptase (Reverse transcriptase)) is performed and synthesized into cDNA. In order to analyze the fusion site of FGFR3-TACC3, the fusion site of interest was confirmed using the UCSC genome browser, and primers were prepared to identify the FGFR3-TACC3 specific region (FW: 5'-TGATCATGCGGGAGTGCTG-3', RV: 5'-CTCCTCACACCTGCTCCTC-3'). The prepared primers were used to perform a PCR experiment on the cDNA to confirm whether the FGFR3-TACC3 fusion specific region was amplified. At the same time, GAPDH was also confirmed as a control group. As a result, GBM15-682T, GBM14-526T, and BT16-1154T were identified as FGFR3-TACC3 fusions (PCR expected size, 400-500bp). Among them, GBM15-682T and GBM14-526T are expected to be the same fusion, and BT16-1154T is expected to be a different fusion. Figure 6b ]. Based on cells derived from patients with FGFR3-TACC3 fusion brain tumors, the properties and anti-cancer effects of further FGFR3 antibody clones were analyzed.
[0452] Example 11: Evaluation of cell binding ability of FGFR3 antibodies; FACS analysis
[0453] In order to confirm the binding ability of the excavation antibody derived from the FGFR3-TACC3 overexpression patient cells confirmed in the present invention, FACS analysis was performed. Each cell was distributed at 3.0-5.0E+05 cells / tube, and after a washing (PBS) step, it was treated with 100-200nM of the excavation antibody at 4 degrees. After that, the unattached antibody sample was removed by the same washing method and treated with anti-human alexa-488 conjugate (Catalog # A-11013, Invitrogen) antibody, and the BD FACSAria TM III (BD Biosciences) detects antibodies attached to the cell surface to confirm cell surface binding ability. Figure 7a ). Under the same conditions, the F309 clone was analyzed for its cell surface binding ability according to the concentration, and it was confirmed that it had a cell surface binding ability proportional to the concentration, thereby verifying its FGFR3-specific binding ability ( Figure 7b For cell lines that do not express FGFR3, their binding was further analyzed ( Figure 7c ).
[0454] Example 12: Evaluation of the targeted degradation rate of FGFR3 antibodies; FACS
[0455] The FGFR3 targeting degradation rate of the candidate antibodies discovered in the present invention was screened by FACS. Typically, the patient-derived cells of GBM15-682T, which are FGFR3 overexpressing cells, were subcultured and distributed at 3.0E+05 cells / tube, and were treated with 40ug / ml of the candidate antibodies (2 hours, 37 degrees). Afterwards, after washing 2-3 times, FGFR3-PE (FAB766P, R&D) was treated and reacted at 4 degrees for 1 hour. Washed 2-3 times by the same method, and then BD FACSAria TM III (BD Biosciences) was used for analysis. It can compare the total FGFR3 expression level on the cell surface after antibody treatment. Compared with the IgG control, the comparative analysis was based on the geometric mean. By the same method, the antibody was treated by time (4 hours, 2 hours, 1 hour, 30 minutes, 15 minutes) to confirm the cell surface FGFR3 degradation rate of the excavation antibody according to time. The same operation was performed in the KMS11 cell line.
[0456] For the antibodies that were preferentially discovered, a relative comparison was performed under the same conditions and at one concentration. On this basis, it was confirmed that F309 and FS306 antibodies effectively reduced the expression of FGFR3 ( Figure 8 ). In addition, in the case of F309 and FS306 clones, the total FGFR3 expression on the cell surface decreased over time, which further confirmed that these clones had FGFR3 degradation rates. In addition, it is believed that F309 and FS306 antibodies have significant degradation rates compared to other antibodies such as B701 and LY3076226 (D11). ( Fig.10a )
[0457] Example 13: FGFR3 epitope domain mapping
[0458] FGFR3 is composed of three domains. Therefore, in order to analyze and discover the FGFR3 binding domain of the antibody, an Fc tag is attached to each domain (FGFR3 Ig domain I, domain II, domain III), and the antibody is produced and purified using a mammalian cell protein expression system. Fig.9c The binding capacity of the purified domain antibodies was analyzed in the same manner as the above ELISA, with the post-treatment antibodies coated at 1 ug / ml and TMB color reaction induced for measurement. It was confirmed that the F309 and FS306 clones specifically bound to the FGFR3 domain 1 ( Figure 9b ). As reported in the literature, B701 (Vofatamab, Rainier Therapeutics) and D11 (LY3076226, Eli Lilly) as comparison group antibodies were confirmed to bind between domain No. 2 and domain No. 3. However, domain No. 2 performed in the present invention contains the epitope of the comparison group antibody. In addition, it is reported that FGFR3 and ligands such as FGF1 and FGF9 bind to Ig domain II and domain III of FGFR3. Based on this, a competition ELISA assay was performed. As a result, as expected, B701 and D11 antibodies showed a situation in which they competed with FGF ligands for binding to FGFR3, but it was observed that F309 antibody bound to FGFR3 regardless of FGF ligand. This can be judged as supporting evidence for binding to the above-mentioned FGFR3 Ig domain I. ( Figure 9a )
[0459] Example 14: Evaluation of the targeted degradation rate of FGFR3 antibodies; Western blotting
[0460] The FGFR3 targeted degradation rate of the candidate antibodies discovered in the present invention was verified by protein immunoblotting. Similar to the FACS method, GBM15-682T patient-derived cells were used as representative cells. The cells were distributed into a 6-well plate at 2.0E+06 cells / well, each antibody was treated at a concentration of 30ug / ml, and reacted at 37 degrees for 3 hours. After that, the lysate was prepared, 20ug of each sample was calculated by Bradford quantification, and protein immunoblotting was performed. Total FGFR3 was observed with sc-13121 antibody. The KMS11 cell line was also experimented with the same concentration and reaction conditions. Similar to the FACS results, it was confirmed that the total FGFR3 degradation rate of F309 and FS306 clones was excellent. ( Fig.10b )
[0461] Example 15: Antibody cellular internalization; Immunocytochemistry (ICC)
[0462] The cell internalization mechanism of the antibody was further verified by the ICC method. GBM15-682T was used as FGFR3 overexpressing cells, and U87MG was used as low-expressing cells. In the case of patient-derived cells of GBM15-682T, since they were not attached to the ICC slide, the PLO reagent was pre-coated and the cells were cultured thereon. In the case of U87MG, as adherent cells, no PLO treatment was performed. First, as a cell internalization condition, cells attached to the ICC slide were treated with 30ug / ml of each antibody and reacted at 37 degrees for 2 hours. The cell internalization non-activation condition is to react for 2 hours at the same concentration and 4 degrees. Afterwards, it was washed and fixed with 2% PFA (10 minutes, 4 degrees). The same washing method was performed again, and 0.1% Triton-X was reacted at room temperature for 3 minutes to penetrate the cells and washed again. Then, it was blocked with 1% BSA for 30 minutes at room temperature and treated with the first antibody overnight at 4 degrees. The first antibody used was LAMP-1 antibody and anti-human IgG, which are lysosomal markers. The next day, the cells were washed and reacted with the second antibody at 4 degrees and in the dark for 1 hour. The second antibody used an antibody with fluorescent coloring that detects the first antibody (Alexa 488; anti-human LAMP1, Alexa 594; anti-human IgG). After washing, DAPI staining was performed, and then each sample was analyzed by confocal microscopy. The analysis results confirmed that the F309 and FS306 clones were attached to the surface of GBM15-682T, which is a FGFR3 overexpressing cell, when treated at 4 degrees, and that they were internalized into the cell at 37 degrees, so the antibody was observed to be in the same lysosomal location (LAMP-1). On this basis, it is predicted that the clone will be internalized by the cell after binding to the cell surface FGFR3 and degraded in the lysosome. ( Fig.11a )
[0463] Example 16: Targeted degradation mechanism of FGFR3 antibody; Analysis of antibody mechanism via lysosomal inhibition
[0464] In the present invention, in order to illustrate the FGFR3 targeting degradation mechanism of the above-mentioned excavation antibody, verification by lysosomal inhibitors was carried out. It is reported that there is the following mechanism, when the antibody is combined with the cell surface specific antigen, the cell internalization (Receptor mediated endocytosis) mediated by the receptor (antigen) is carried out and the receptor and the antibody are degraded together in the lysosome. Therefore, the degradation of the antibody in the lysosome that has confirmed the degradation rate of FGFR3 in the FGFR3 antibody is verified, and the total FGFR3 level of the sample treated with the lysosomal inhibitor and the sample not treated with the lysosomal inhibitor is confirmed by protein immunoblotting. GBM15-682T is distributed in 6-well plates with 1.5E+06 cells / well, and is treated with concanamycin (Concanamycin) known as a lysosomal inhibitor at a concentration of 100nM for 2 hours under 37 degrees. As a control group, it is treated with DMSO. After 2 hours, each antibody is treated for 3 hours under the conditions of 30ug / ml and 37 degrees. Afterwards, the same method as the above-mentioned protein immunoblotting method was used to confirm the total FGFR3 level. Even when F309 and FS306 clones were treated with concanavalin A, a lysosomal inhibitor, the total FGFR3 did not decrease, and when concanavalin A, a lysosomal inhibitor, was not treated, the total FGFR3 decreased significantly. It is believed that F309 and FS306 clones adhere to the cell surface FGFR3 and then are internalized by the cell, thereby being degraded together with FGFR3 in the lysosome. ( Fig.11b )
[0465] Example 17: Signaling pathway inhibition assay; Western blotting
[0466] FGFR3 sub-signaling inhibition analysis was performed by protein immunoblotting. In the same manner as the above-mentioned protein immunoblotting method, GBM15-682T patient-derived cells were distributed in 6-well plates and treated with 30ug / ml of each antibody (37 degrees, 3 hours). Afterwards, in order to activate FGFR3-related sub-signaling, 50ng / ml of FGF1 and FGF9 representative ligands were treated (together with 50ug / ml of heparin sulfate (heparin sulfate) treatment) and reacted at 37 degrees for 30 minutes. Afterwards, lysates were prepared and protein immunoblots were performed on 20ug of each sample. Phosphorylation and activation of FGFR3 sub-signaling pathways were verified using the following antibodies; p-FGFR3 (ab155960, Abcam), p-ERK (4370s, CST), p-AKT (9271s, CST). It was confirmed that the F309 and FS306 clones inhibited p-FGFR3, p-ERK, and p-AKT, which are sub-signaling pathways of FGFR3. Fig.12 )
[0467] Example 18: Analysis of cancer cell growth inhibition ability; ligand-dependent environment
[0468] In order to confirm the ability of the antibody discovered in the present invention to inhibit cancer cell growth in a ligand-dependent environment, GBM15-682T was distributed in a 96-well black-flat bottom plate at 10,000 cells / well under serum-free conditions. After starvation for one day, the cells were treated with FGF1 (232-FA, R&D) and FGF9 (273-F9, R&D) as ligands on the second day to a final concentration of 50 ng / ml, and the antibodies were serially diluted and treated at various concentrations. After that, the cells were cultured in a CO2 incubator at 37 degrees for 7 days. Cell growth was performed by The Luminescent Cell Viability Assay was used to measure and compare the cell growth of the antibody-treated group with that of the control group. When the cells were treated with the ligand, it was confirmed that the ligand accelerated cancer growth by about 1.5-2 times. Therefore, it was confirmed that when the clones were treated with each concentration, cell growth was inhibited by 20-30% compared to the IgG control (control group). ( Fig.13a )
[0469] Example 19: Analysis of cancer cell growth inhibition ability; ligand-independent environment
[0470] Based on the cell growth measurement method described in the present invention, the cancer cell growth inhibition ability of the antibody was evaluated in a ligand-independent environment. GBM15-682T patient-derived cells were distributed in a 96-well black flat-bottom plate at 10,000 cells / well, and the antibody was serially diluted and treated at various concentrations. After that, it was cultured in a CO2 incubator at 37 degrees for 7 days. Cell growth was performed by The luminescent cell activity assay was measured and the cell growth of the antibody-treated group was compared to the control group. When treated with antibodies in an environment without ligands, it was confirmed that the F309 and FS306 clones inhibited cell growth by 30-40% compared to the IgG control (control group). In U87MG, a FGFR3 low-expressing cell line, and patient-derived cells (626T), no cancer cell growth inhibition ability was observed. This is considered to be a growth inhibition feature based on FGFR3 expression. ( Fig.13b )
[0471] Example 20: In vivo short-term PK analysis and efficacy evaluation in xenograft models
[0472] Short-term PK was performed to confirm whether initial clearance occurred when the excavation antibody was administered in vivo. 10 mg / kg of the antibody was administered to Balb / c mice, and blood samples were collected from each individual immediately after administration, at intervals of 1 hour, 2 hours, 4 hours, 1 day, and 2 days. In order to remove blood cells from the blood, plasma was obtained by centrifugation, and the antibody titer in the plasma was quantified based on ELISA. As a result, it was confirmed that, similar to the control antibody, both F309 and FS306 antibodies had normal initial antibody PK, and were not cleared in the early stage. ( Fig.14a )
[0473] In order to evaluate the in vivo efficacy of the excavated antibody, our research group prepared a xenograft model. GBM15-682T (1.0E+06 cells) was injected subcutaneously into the flank of Bab / c nude mice to form tumors with an average size of 100-150 mm. 3 When tumors were detected, mice were divided into groups of 5 mice each. Antibodies and vehicles were injected intraperitoneally at different concentrations three times or twice a week. Calipers were used and V = 0.5a × b 2 The tumor volume was calculated by the formula (a: length of the long axis of the tumor, b: length of the short axis of the tumor). The weight of the mice was also measured on the same day of tumor measurement. It was confirmed that the administration of 10 mg / kg (three times a week) of F309 and FS306 clones inhibited cancer growth by about 50% and about 40%, respectively. Fig.14aIt is believed that in the case of F309, when administered twice a week at various concentrations (30 mpk, 10 mpk, 3 mpk), it has an excellent anti-cancer effect in inhibiting cancer growth ( Fig.14b ).
[0474] Example 21: F309 antibody affinity maturation engineering
[0475] In order to further improve the significant FGFR3 degradation rate and cancer growth inhibition ability of F309, affinity maturation was performed. A phagemid vector displaying F309 scFv fragments (heavy chain variable site; VH, light chain variable site; VL) on the surface of M13 phage was prepared and used as a library model. For affinity maturation, CDR H1, H2, H3 and CDR L1, L2, L3 were selected based on the Kabat numbering of the antibody, and primers containing NNK degenerate codons were used for each CDR to prepare a F309 mutant library ( Fig.15a ). The above bio-panning (antigen-fixed panning) was performed 3-4 times for each library. On this basis, antibodies with improved affinity relative to the F309 parent antibody were cloned by affinity screening based on ELISA. The clones that were ensured were re-verified by re-production experiments, and finally the affinity mature mutants of F309 were obtained by antibody sequence analysis. Compared with the parent antibody, the F309 mutants that were ensured had significantly improved specific binding ability to the FGFR3 recombinant protein ( Fig.15b ). Further, by combining the amino acid residues of the SSM001-SSM010 mutants, further mutants SSM023, SSM024, SSM026, SSM034, SSM036, SSM234, and SSM236 were designed and prepared. In order to verify the FGFR3 antigen-specific binding ability of the antibodies, ELISA was performed, and the results confirmed that the FGFR3 antigen affinity was further improved. Fig.15b , Fig.15c The biological activity of the mutant antibody was analyzed in GBM15-682T, and the results confirmed the increased cancer growth inhibition relative to the F309 parent antibody ( Fig.15d ).
[0476] [Table 7]
[0477]
[0478]
[0479] [Table 8]
[0480]
[0481]
[0482] [Table 9]
[0483]
[0484]
[0485] [Table 10]
[0486]
[0487] [Table 11] [rhFGFR3-IIIb specific binding ability: EC measured by direct binding ELISA 50 ]
[0488] [First screening]
[0489]
[0490] [Second screening]
[0491]
[0492] [Table 12]
[0493]
[0494] ND: Not defined
[0495] NB: Not bound
[0496] [Table 13]
[0497]
[0498] Example 22: Verification of the applicability of F309 antibody as an ADC
[0499] In the case of antibody-drug conjugates, the following mechanism is present: the antibody specifically binds to the antigen on the cell surface, is introduced into the cell through receptor-mediated cellular internalization, and is degraded by lysosomes and proteases inside the cell, thereby killing the cell through the conjugated toxic substances. This antibody-drug conjugate is widely used as a new generation of antibody therapeutic agent platform as a platform that can maximize the therapeutic effect. In the present invention, it is desired to confirm the applicability of clones with excellent internalization and targeted degradation rates for FGFR3 and FGFR3-TACC3 fusion cells as antibody-drug conjugates. As described in the present invention, the FGFR3 targeted degradation rate and cellular internalization of F309 and FS306 clones have been verified, so it is judged that F309 and FS306 clones can be used as antibody-drug conjugate platforms, and thus implemented. Among them, the preparation of the antibody-drug conjugate of the F309 clone uses PerKit TM Antibody MMAE Conjugation Kit (PerKit TM Antibody MMAE Conjugation Kit) (CellMosaic), a first-generation antibody-drug conjugate technology (a method developed by Seattle Genetics: Sun et al. 2005, Bioconjugate Chem. 16, 1282-1290), is a method of randomly conjugating -vc MMAE to the interchain disulfide of the antibody ( Fig.16a ). Various patient-derived cells and cancer cell lines were selected as FACS expression criteria and relatively grouped into high, medium, and low, and the cytotoxicity test of F309 was performed on them. The evaluation method is as described in the present invention, by The results showed that F309-vc MMAE showed significant cytotoxicity in proportion to the expression level of FGFR3 on the cell surface. Figure 16b to Figure 16c ), in order to ensure further competitiveness, the LY3076226 parent antibody in clinical development as FGFR3-ADC was applied with the same kit to compare the effects. F309-vc MMAE showed superior cytotoxicity to LY3076266-vc MMAE in GBM15-682T as FGFR3-TACC3 fusion. The cell growth inhibition effect of ADC according to each FGFR3 expression amount was analyzed by IC50 and maximum inhibition, and marked in ( Fig.16d ) in the table.
[0500] Example 23: Epitope domain mapping and antigen affinity analysis of affinity matured antibodies
[0501] The affinity matured antibody F309#SSM236 (hereinafter, AMB302#1.2) was also subjected to the epitope domain mapping performed previously. In the case of the parental antibody, binding to domain D1 was confirmed, and when the same domains (domain I, domain II, domain III) were used for analysis, the affinity matured antibody also specifically bound to domain D1. In the case of the antibody, specific binding ability to human / cynomolgus macaque (cyno) FGFR3 was confirmed again ( Fig.17 ). The KD values of each antigen are shown in Table 14 below.
[0502] Table 14. Binding analysis of affinity matured variant antibodies using the biomacromolecule interaction analysis system (Biacore) (SPR analysis) (KD constant)
[0503]
[0504] Example 24: Evaluation of Cellular Internalization and Targeted Degradation Rate of Affinity Matured Antibodies
[0505] For the F309 variant with fairly mature affinity, the FGFR3 target on the cell surface was verified to be effectively degraded. By the same method as in the previous invention, first, the confirmation of FGFR3 cell surface expression and cell internalization evaluation were verified by FACS, and the targeted degradation rate was performed by protein immunoblotting. In the case of the affinity mature variant, it was confirmed that there was considerable cell internalization efficacy and targeted degradation rate ( Figures 18 to 20 ).
[0506] Example 25: Mouse / Monkey PK Analysis of Affinity Matured Antibodies
[0507] In order to verify the in vivo PK spectrum of affinity matured antibodies (AMB302#1.2, SSM236), mice / monkey individuals were analyzed. 10mg / kg, 1mg / kg, and 0.1mg / kg of monoclonal antibodies were administered to BALB / c mice (8 weeks, ~20g, n=3, female), and three surviving individuals were crossed at intervals of immediately, 10 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 24 hours, 2 days, 3 days, 7 days, 10 days, 14 days, 17 days, 21 days, and 28 days after administration, and blood was collected from the eye sockets at each time. In order to remove blood cells from the blood, plasma was ensured by a centrifuge, and the antibody titer in the plasma was quantified based on quantitative ELISA. As a result, it was confirmed that in the case of AMB302#1.2 antibody, it has a stable half-life (t1 / 2) characteristic and CL of more than 10 days in the mouse body. In addition, no biologically specific clinical side effects and body weight changes were observed at all administered concentrations ( Fig.21 ).
[0508] In a monkey individual (2-3 years, ~3 kg, female, natural ) was administered 25 mg / kg in mice, followed by a single administration of 50 mg / kg, and blood samples were collected at each time (10 minutes, 1 hour and 6 hours, 1 day, 2 days, 3 days, 7 days, 10 days, 14 days, 21 days and 28 days). In order to remove blood cells from the obtained blood, plasma was ensured by a centrifuge, and antibodies in the plasma were quantified by quantitative ELISA. As a result, a stable half-life (more than 10 days) and CL tendency similar to the results in mice were confirmed. In addition, no biologically specific clinical side effects and body weight changes were observed at all administration concentrations ( Fig. 22 ).
[0509] Example 26: ADC preparation of affinity matured antibodies
[0510] The variants obtained by affinity maturation engineering in the present invention are subjected to ADC preparation ( Fig.23 ). The purified antibody sample was treated with tris(2-carboxyethyl)phosphine hydrochloride (TCEP) at an equivalent ratio of 8.0 or more and completely reduced at 37 degrees for 2 hours. After reduction, the buffer was exchanged with PBS at pH 7.4, and the sample was conjugated with the antibody reduced together with the linker-payload (Topoisomerase I inhibitor (Topoisomerase I inhibitor, equivalent ratio of 10.0) dissolved in DMA at 37 degrees for 2 hours. After conjugation, the buffer was exchanged through a centrifugal column (Amicon Ultra-15 Centrifugal Filter Units).
[0511] The same method was used to partially reduce the antibody to prepare ADCs conjugated with linkers-payloads (Duocarmycin derivatives, linker-AMB401) ( Fig.24 ).
[0512] Example 27: Affinity Matured Antibody ADC Analysis (TOPOI)
[0513] For the completed synthesized ADC samples (TOPOI conjugated ADC), antigen affinity was confirmed by ELISA, which was performed by the same method as the affinity ELISA performed in the present invention, and confirmed to have the same antigen binding ability as the parent antibody. In addition, the high purity physical performance characteristics of the prepared ADC were confirmed by SEC-HPLC analysis.
[0514] DAR analysis was performed by LC-MS, and mass spectrometry analysis of the linker-payload attached to the heavy chain and light chain of the prepared ADC was performed, and when the mass spectrometry was converted, it was confirmed that the DAR was about 6 or more ( Fig.25 ).
[0515] Example 28: Analysis of affinity matured antibody ADC (duocarmycin, linker-AMB401)
[0516] For the ADC sample (duocarmycin, linker-AMB401; ADC) synthesized, the substance was analyzed by SEC-HPLC for purity and HIC-HPLC and PLRP for DAR. In the case of this substance, it was confirmed that it had a purity of more than 98% and a uniform physical property characteristic of about 4 DAR ( Fig.26 : 20 mM histidine-acetate, pH 6.0.
[0517] Example 29: Efficacy Evaluation of Affinity Matured Variant ADCs in Patient-Derived Organoid Ex Vivo Models (ADC-TOPOI)
[0518] Using the prepared ADC, the efficacy of organoids from patients with overexpression of FGFR3 (TACC3 fusion) was evaluated. Single spheroid organoid models were prepared by separating cancer cells from cancer tissues from brain tumor patients. Two patient-derived cells (AMB-BT-0050T, AMB-BT-0112T) with FGFR3-TACC3 fusion and patient-derived cells (AMB-BT-0013T) without FGFR3-TACC3 fusion were cultured overnight to form a single spheroid, which was then treated with ADC and the results were confirmed after one week of culture. According to the analysis, in the negative control, there was no difference in sensitivity between ADC and control ADC, and compared with the control ADC, in two patient-derived cells with FGFR3-TACC3 fusion, spheroid growth was specifically and significantly inhibited and cell death was induced in proportion to the FGFR3 expression. In particular, in the case of affinity-matured variant antibody-ADC, it was confirmed that significantly increased cytotoxicity and cell death were induced in FGFR3 (TACC3 fusion) overexpressing cells compared to the parent antibody-ADC. For FGFR3 (TACC3 fusion) overexpressing cells, an IC50 of less than 0.3 nM was shown, and for negative cells, an IC50 of more than 90 nM was shown ( Fig. 27 ).
[0519] Example 30: Evaluation of affinity matured variant ADC efficacy in an in vitro patient-derived organoid model (ADC-duocarmycin, linker-AMB401)
[0520] The in vitro efficacy evaluation of AMB302#1.2-fold oncomycin ADC was performed by the same method as in Example 27. It showed a low IC50 of about 0.3 nM for cells from patients with brain tumors overexpressing FGFR3 (TACC3), and a high IC50 of more than 100 nM for negative cells. This indicates that the ADC induces cell death significantly proportional to FGFR3 expression ( Fig.28 ).
[0521] Example 31: Evaluation of ADC efficacy in a stereotactic animal model of FGFR3 (TACC3 fusion) brain tumors (ADC-TOPOI)
[0522] Evaluation of increased survival in stereotactic animal models of brain tumors (brain tumors, GBM) treated with ADCs Fig.29). Patient-derived cells of AMB-BT-0050T (682T) as FGFR3 overexpressing cells were cultured, and 2×10^5 cells were mixed with 5ul of culture medium for preparation. The prepared cell line was injected at a depth of 3.2mm at the position of 1.7mm to the left and 0.5mm above the anterior fontanel of immunodeficient mice to make a brain tumor mouse model. A total of 4 groups were divided into control, control-TOPOI, AMB302#1.2-TOPOI (single administration, multiple administration), and 7 mice were used for evaluation in each group. The candidate drug was administered by intravenous injection once on the seventh day after the model was made. On the 15th day, 2 mice were taken from each group for intermediate sampling for biomarker analysis, etc. The weight of the mice was measured twice a week, and euthanasia was performed to extract the brain of the mice when there was a weight loss of more than 20%. It was confirmed that the survival period of mice increased by more than 70% with only a single administration of AMB302#1.2-TOPOI.
[0523] When AMB302#1.1-TOPO1 was administered twice (10 mg / kg, one week apart) in the same model, the survival period of mice was also significantly increased by more than 100%. In addition, when the tumor size of the mouse brain was compared by intermediate sampling, no tumors were found in the ADC-treated individuals compared to the control group. In addition, it was confirmed that the affinity-matured ADC induced a clear improvement in tumor suppression and an increase in survival rate compared to the ADC based on the parent antibody ( Fig.30 ).
[0524] Example 32: Evaluation of ADC efficacy in FGFR3 (TACC3 fusion) subcutaneous transplant model (ADC-TOPOI)
[0525] RT112 cells (1.0E+06 cells) were injected subcutaneously (sc) into the flanks of Bab / c nude mice to form tumors with an average size of 100-150 mm 3 At this time, the mice were divided into groups again, and 5 mice were assigned to each group. Each group was intravenously injected with ADC and vehicle twice (one week apart, 5 mp / kg). A caliper was used and V = 0.5a × b 2 The tumor volume was calculated using the formula (a: length of the long axis of the tumor, b: length of the short axis of the tumor). The weight of the mice was also measured on the same day as the tumor was measured. When ADC-TOPOI was administered, it was confirmed that cancer growth was completely inhibited, thus confirming that it had an excellent anti-cancer effect ( Fig.31 ).
[0526] Example 33: Evaluation of ADC efficacy in a stereotactic animal model of FGFR3 (TACC3 fusion) brain tumor (ADC-duocarcin, linker-AMB401)
[0527] In the same model as above, single administration (10 mg / kg) or multiple administration (10 mg / kg, Q4D) of AMB302#1.1-AMB401 was performed to evaluate the efficacy. A significant increase in the survival rate was confirmed in the corresponding ADC administration group, especially in the group with multiple administrations, the survival rate was confirmed to be increased by more than 30% ( Fig.32 ).
[0528] Above, specific parts of the present invention are described in detail. For those skilled in the art, it is obvious that such specific technology is only a preferred embodiment, and the scope of the present invention is not limited thereto. Therefore, the substantive scope of the present invention will be defined by the claims and their equivalents. <110> IonDe Biotechnology Co., Ltd. <120> Anti-FGFR3 antibodies and uses thereof <130> KHP212111770.2 <160> 219 <170> PatentIn Version 3.2 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 1 Ser Tyr Tyr Met Ser 1 5 <210> 2 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 2 Asp Tyr Tyr Met Ser 1 5 <210> 3 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 3 Gly Tyr Ala Met Ser 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 4 Asn Tyr Tyr Met Ser 1 5 <210> 5 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 5 Ser Tyr Asp Met Ser 1 5 <210> 6 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 6 Asp Tyr Asp Met Ser 1 5 <210> 7 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 7 Asn Tyr Ala Ile His 1 5 <210> 8 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 8 Asn Tyr Trp Ile Gly 1 5 <210> 9 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 9 Asp Ile Ala Met His 1 5 <210> 10 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 10 Ser Tyr Ala Ile Ser 1 5 <210> 11 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 11 Ile Tyr Gly Met His 1 5 <210> 12 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 12 Asn Tyr Trp Met Thr 1 5 <210> 13 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 13 Asn Tyr Pro Met Ser 1 5 <210> 14 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 14 Ser Tyr Ala Met Ser 1 5 <210> 15 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 15 Gly Tyr Asp Met Ser 1 5 <210> 16 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 16 Asn Tyr Asp Met Ser 1 5 <210> 17 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 17 Gly Tyr Tyr Met Ser 1 5 <210> 18 <211> 5 <212> PRT <213> Artificial sequence <220> <223> VH CDR1 <400> 18 Asn Tyr Ala Met Ser 1 5 <210> 19 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 19 Ala Ile Ser Pro Gly Ser Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 20 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 20 Ala Ile Tyr His Gly Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> twenty one <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> twenty one Ala Ile Ser His Gly Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> twenty two <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> twenty two Gly Ile Ser Pro Gly Ser Gly Ser Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> twenty three <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> twenty three Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> twenty four <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> twenty four Gly Ile Tyr Tyr Gly Ser Gly Asn Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 25 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 25 Ala Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 26 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 26 Ser Ile Ile Pro Ile Ser Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 27 <211> 17 <212> PRT <213> artificial sequence <220> <223> VH CDR2 <400> 27 Ile Ile His Pro Gly Gly Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln 1 5 10 15 Gly <210> 28 <211> 16 <212> PRT <213> artificial sequence <220> <223> VH CDR2 <400> 28 Thr Ile Tyr Ser Ser Asp Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Gly 1 5 10 15 <210> 29 <211> 16 <212> PRT <213> artificial sequence <220> <223> VH CDR2 <400> 29 Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 30 <211> 16 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 30 Ser Ile Tyr Tyr Thr Gly Asp Thr Tyr Ser Ser Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 31 <211> 16 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 31 Ser Ile Tyr Tyr Ser Gly Asp Thr Tyr Tyr Asn Pro Ser Leu Glu Ser 1 5 10 15 <210> 32 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 32 Trp Ile Asn Thr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 1 5 10 15 Thr <210> 33 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 33 Gly Ile Asn Trp Arg Gly Ala Thr Thr Ala Tyr Ala Asp Ser Leu Lys 1 5 10 15 Gly <210> 34 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 34 Ser Val Ser Gly Ser Gly Thr Ser Thr Tyr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 35 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 35 Gly Val Ser Tyr Ser Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Leu Gln 1 5 10 15 Ser <210> 36 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 36 Gly Ile Tyr Pro Asp Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 37 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 37 Val Ile Ser Pro Ser Gly Gly Asn Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 38 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 38 Val Ile Phe His Asp Ser Gly Asn Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 39 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 39 Ala Ile Ser Ser Gly Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 40 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 40 Gly Ile Ser Ser Asp Asn Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 41 <211> 17 <212> PRT <213> Artificial sequence <220> <223> VH CDR2 <400> 41 Val Ile Tyr His Asn Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 42 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 42 Asp Trp Ser Lys Phe Asp Tyr 1 5 <210> 43 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 43 Asp Ser Arg Leu Cys Gln Thr Ser Gly Cys Tyr Ser Asp Asp Ala Met 1 5 10 15 Asp Val <210> 44 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 44 Ser Arg Leu Glu Ser Pro Phe Leu Ala Gln Ser Tyr Ala Tyr Ala Met 1 5 10 15 Asp Val <210> 45 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 45 Asp Trp Thr Arg Phe Asp Tyr 1 5 <210> 46 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 46 Asp Ala Pro Thr Asn Glu Met Ser Arg Phe Asp Tyr 1 5 10 <210> 47 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 47 Gly Gly Gly Gly Phe Asp Tyr 1 5 <210> 48 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 48 His Leu Pro Asn Phe Asp Tyr 1 5 <210> 49 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 49 Gly Gly Tyr Gly Phe Asp Tyr 1 5 <210> 50 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 50 Trp Arg Ala Trp Phe Asp Ser 1 5 <210> 51 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 51 Gly Val Gly Tyr Thr Thr Ser Ser Arg Phe Asp Tyr 1 5 10 <210> 52 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 52 Gly Ala Ser Trp Met Asp Met 1 5 <210> 53 <211> 8 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 53 Gly Tyr Ala Thr Ala Leu Asp Tyr 1 5 <210> 54 <211> 10 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 54 Asp Ile Gly Ser Ser Trp Gly Phe Asp Tyr 1 5 10 <210> 55 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 55 Gly Arg Gly Met Phe Asp Tyr 1 5 <210> 56 <211> 8 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 56 Ser Asp Tyr Gly Leu Phe Asp Ile 1 5 <210> 57 <211> 10 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 57 His Thr Gln Arg Trp Gly Ala Phe Asp Pro 1 5 10 <210> 58 <211> 8 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 58 Asn Arg Asn Ala Ile Phe Asp Tyr 1 5 <210> 59 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 59 Asp Pro Leu Ile Tyr Glu Leu Pro Ile Gly Tyr Ser Ser Tyr Gly Met 1 5 10 15 Asp Val <210> 60 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 60 Gly Pro Asn Ser His Ile Tyr Pro Tyr Phe Tyr Tyr 1 5 10 <210> 61 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 61 Gly Ile Leu Phe Met Thr Ile Thr Leu Pro Tyr Ser Ser Asp Gly Met 1 5 10 15 Asp Val <210> 62 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 62 His Pro Leu Leu Ser Ile Phe Ser Leu Pro Tyr Tyr Ser Asp Ala Met 1 5 10 15 Asp Val <210> 63 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 63 Lys Trp Pro Thr Phe Asp Tyr 1 5 <210> 64 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 64 Asp Trp Glu Gln Phe Asp Tyr 1 5 <210> 65 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 65 His Thr Val Ile Glu Ala Leu Glu Ala Ala Tyr Tyr Asp Asp Gly Met 1 5 10 15 Asp Val <210> 66 <211> 18 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 66 His Gly Gly Asp Glu Thr Asn Tyr Phe Gln Ser Tyr Tyr Asp Gly Met 1 5 10 15 Asp Val <210> 67 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 67 Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn Asp Val Thr 1 5 10 <210> 68 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 68 Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 69 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 69 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Asp Val Ser 1 5 10 <210> 70 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 70 Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Ala Val Ser 1 5 10 <210> 71 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 71 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 72 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 72 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Asp Val Tyr 1 5 10 <210> 73 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 73 Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Thr Val Ser 1 5 10 <210> 74 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 74 Arg Ala Ser Gln Ser Ile Ser Thr Phe Leu Asn 1 5 10 <210> 75 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 75 Arg Ala Ser Gln Ser Ile Thr Asp Tyr Leu Ala 1 5 10 <210> 76 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 76 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 77 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 77 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 78 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 78 Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 79 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 79 Thr Ala Ala Ala Ser Asp Ile Ala Ser Asn Tyr Val Gln 1 5 10 <210> 80 <211> 10 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 80 Ser Asp Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 81 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 81 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 82 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 82 Gly Gly Asp Asn Ile Gly Thr Lys Ser Val His 1 5 10 <210> 83 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 83 Ser Arg Asn Asn Ile Gly Ser Lys Ser Met His 1 5 10 <210> 84 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 84 Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn Asp Val Asn 1 5 10 <210> 85 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 85 Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn Ala Val Thr 1 5 10 <210> 86 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 86 Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Asp Val Ser 1 5 10 <210> 87 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 87 Thr Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Tyr 1 5 10 <210> 88 <211> 13 <212> PRT <213> Artificial sequence <220> <223> VL CDR1 <400> 88 Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn Thr Phe Asn 1 5 10 <210> 89 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 89 Asp Asp Asn His Arg Pro Ser 1 5 <210> 90 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 90 Tyr Asn Ser His Arg Pro Ser 1 5 <210> 91 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 91 Ser Asn Ser His Arg Pro Ser 1 5 <210> 92 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 92 Asp Asp Ser Lys Arg Pro Ser 1 5 <210> 93 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 93 Ala Asp Ser Lys Arg Pro Ser 1 5 <210> 94 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 94 Ala Asp Asn His Arg Pro Ser 1 5 <210> 95 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 95 Tyr Asp Ser His Arg Pro Ser 1 5 <210> 96 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 96 Asp Ala Thr Asn Arg Ala Thr 1 5 <210> 97 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 97 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 98 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 98 Asp Ala Ser Asn Arg Ala Ala 1 5 <210> 99 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 99 Asp Thr Ser Asn Lys His Ser 1 5 <210> 100 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 100 Glu Asp Thr Lys Arg Pro Ser 1 5 <210> 101 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 101 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 102 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 102 Gln Asp Thr Lys Arg Pro Ser 1 5 <210> 103 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 103 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 104 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 104 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 105 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 105 Tyr Asp Ser Asn Arg Pro Ser 1 5 <210> 106 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 106 Ser Asp Asn His Arg Pro Ser 1 5 <210> 107 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 107 Ala Asn Asn Gln Arg Pro Ser 1 5 <210> 108 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 108 Ser Asn Ser Gln Arg Pro Ser 1 5 <210> 109 <211> 7 <212> PRT <213> Artificial sequence <220> <223> VL CDR2 <400> 109 Ser Asp Ser Asn Arg Pro Ser 1 5 <210> 110 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 110 Gly Thr Trp Asp Ala Ser Leu Ser Ala Tyr Val 1 5 10 <210> 111 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 111 Ala Thr Trp Asp Asp Ser Leu Ser Gly Tyr Val 1 5 10 <210> 112 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 112 Gly Thr Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 113 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 113 Gly Ala Trp Asp Tyr Ser Leu Ser Ala Tyr Val 1 5 10 <210> 114 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 114 Ala Ser Trp Asp Tyr Ser Leu Ser Gly Tyr Val 1 5 10 <210> 115 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 115 Gly Ala Trp Asp Ala Ser Leu Asn Gly Tyr Val 1 5 10 <210> 116 <211> 9 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 116 Gln Gln Ala Asn Ser Phe Pro Leu Thr 1 5 <210> 117 <211> 9 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 117 Gln Gln Ser Tyr Ser Thr Pro Phe Thr 1 5 <210> 118 <211> 10 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 118 Cys Gln Gln Tyr Ser Ser Phe Pro Leu Thr 1 5 10 <210> 119 <211> 9 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 119 Gln Gln Ser Tyr Ser Thr Pro Ile Thr 1 5 <210> 120 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 120 Ala Ala Trp Asp Asn Ser Leu Asn Gly Gln Leu 1 5 10 <210> 121 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 121 Ala Thr Trp Asp Asp Ser Leu Arg Gly Trp Val 1 5 10 <210> 122 <211> 9 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 122 Gln Ser Tyr Asp Ser Ser Thr Val Val 1 5 <210> 123 <211> 9 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 123 Gln Ser Tyr Asp Ser Arg Gln Leu Val 1 5 <210> 124 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 124 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Tyr Val 1 5 10 <210> 125 <211> 10 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 125 Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val 1 5 10 <210> 126 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 126 Ala Ala Trp Asp Ser Ser Leu Ser Gly Tyr Val 1 5 10 <210> 127 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 127 Gly Thr Trp Asp Tyr Ser Leu Ser Gly Tyr Val 1 5 10 <210> 128 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 128 Gly Ala Trp Asp Asp Ser Leu Ser Ala Tyr Val 1 5 10 <210> 129 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 129 Gly Ala Trp Asp Ser Ser Leu Asn Ala Tyr Val 1 5 10 <210> 130 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 130 Gly Thr Trp Asp Asp Ser Leu Ser Gly Tyr Val 1 5 10 <210> 131 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 131 Gly Ala Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 132 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 132 Gly Thr Trp Asp Tyr Ser Leu Asn Gly Tyr Val 1 5 10 <210> 133 <211> 116 <212> PRT <213> Artificial sequence <220> <223> VH <400> 133 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Pro Gly Ser Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Trp Ser Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 134 <211> 127 <212> PRT <213> artificial sequence <220> <223> VH <400> 134 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ser Trp Val Arg Leu Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Tyr His Gly Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Ser Arg Leu Cys Gln Thr Ser Gly Cys Tyr Ser Asp Asp 100 105 110 Ala Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 135 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 135 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser His Gly Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Arg Leu Glu Ser Pro Phe Leu Ala Gln Ser Tyr Ala Tyr 100 105 110 Ala Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 136 <211> 116 <212> PRT <213> artificial sequence <220> <223> VH <400> 136 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Pro Gly Ser Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Trp Thr Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 137 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 137 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Thr Asn Glu Met Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 138 <211> 116 <212> PRT <213> artificial sequence <220> <223> VH <400> 138 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Tyr Gly Ser Gly Asn Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 139 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 139 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys His Leu Pro Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 140 <211> 116 <212> PRT <213> Artificial sequence <220> <223> VH <400> 140 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ile Pro Ile Ser Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Gly Gly Tyr Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 141 <211> 116 <212> PRT <213> Artificial sequence <220> <223> VH <400> 141 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ile Ile His Pro Gly Gly Ser Asp Ser Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Arg Ala Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 142 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 142 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Phe Ser Asp Ile 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Tyr Ser Ser Asp Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Lys Gly Val Gly Tyr Thr Thr Ser Ser Arg Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 143 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 143 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Gln Gly Ala Ser Trp Met Asp Met Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 144 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 144 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Tyr Tyr Thr Gly Asp Thr Tyr Ser Asn Pro Ser Leu Lys 50 55 60 Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Tyr Ala Thr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 145 <211> 118 <212> PRT <213> artificial sequence <220> <223> VH <400> 145 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Tyr Tyr Ser Gly Asp Thr Tyr Tyr Asn Pro Ser Leu Glu 50 55 60 Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Ile Gly Ser Ser Trp Gly Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 146 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 146 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Trp Ile Asn Thr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Thr Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Arg Gly Met Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 147 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 147 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asn Trp Arg Gly Ala Thr Thr Ala Tyr Ala Asp Ser Leu 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Asp Tyr Gly Leu Phe Asp Ile Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 148 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 148 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Pro Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Val Ser Gly Ser Gly Thr Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu His 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Thr Gln Arg Trp Gly Ala Phe Asp Pro Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 149 <211> 117 <212> PRT <213> artificial sequence <220> <223> VH <400> 149 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Val Ser Tyr Ser Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Leu 50 55 60 Gln Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Asn Ala Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 150 <211> 127 <212> PRT <213> artificial sequence <220> <223> VH <400> 150 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Pro Asp Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Pro Leu Ile Tyr Glu Leu Pro Ile Gly Tyr Ser Ser Tyr 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 151 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 151 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Gly Pro Asn Ser His Ile Tyr Pro Tyr Phe Tyr Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 152 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 152 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Ser Pro Ser Gly Gly Asn Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ile Leu Phe Met Thr Ile Thr Leu Pro Tyr Ser Ser Asp 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 153 <211> 127 <212> PRT <213> artificial sequence <220> <223> VH <400> 153 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Phe His Asp Ser Gly Asn Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys His Pro Leu Leu Ser Ile Phe Ser Leu Pro Tyr Tyr Ser Asp 100 105 110 Ala Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 154 <211> 116 <212> PRT <213> artificial sequence <220> <223> VH <400> 154 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Ser Gly Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Lys Trp Pro Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 155 <211> 116 <212> PRT <213> artificial sequence <220> <223> VH <400> 155 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Pro Gly Ser Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Trp Glu Gln Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 156 <211> 127 <212> PRT <213> artificial sequence <220> <223> VH <400> 156 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Ser Asp Asn Ser Ser Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys His Thr Val Ile Glu Ala Leu Glu Ala Ala Tyr Tyr Asp Asp 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 157 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> VH <400> 157 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr His Asn Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys His Gly Gly Asp Glu Thr Asn Tyr Phe Gln Ser Tyr Tyr Asp 100 105 110 Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 158 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 158 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Asp Val Thr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asp Asn His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ala Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 159 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 159 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Tyr Asn Ser His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 160 <211> 110 <212> PRT <213> Artificial sequence <220> <223> VL <400> 160 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Tyr Asn Ser His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 161 <211> 110 <212> PRT <213> Artificial sequence <220> <223> VL <400> 161 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Ala Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asp Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Tyr Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 162 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 162 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asp Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Tyr Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 163 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 163 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asp Asn His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ala Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 164 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 164 Gln Ser Val Leu Thr Gln Leu Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Tyr Asp Ser His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 165 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 165 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Thr Phe 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Thr Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 166 <211> 107 <212> PRT <213> artificial sequence <220> <223> VL <400> 166 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Thr Asp Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 167 <211> 107 <212> PRT <213> artificial sequence <220> <223> VL <400> 167 Glu Ile Val Leu Thr Gln Gly Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Ser Phe Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 168 <211> 107 <212> PRT <213> artificial sequence <220> <223> VL <400> 168 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 169 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 169 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Thr Ser Asn Lys His Ser Gly Asp Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asn Ser Leu Asn Gly 85 90 95 Gln Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 170 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 170 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Ala Ala Ala Ser Asp Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Glu Asp Thr Lys Arg Pro Ser Gly Val Pro Tyr Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Arg Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 171 <211> 105 <212> PRT <213> Artificial sequence <220> <223> VL <400> 171 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Asp Asn Ile Gly Ser Lys Ser Val His 20 25 30 Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser 35 40 45 Asn Asn Gln Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys 50 55 60 Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp 65 70 75 80 Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Thr Val Val Phe 85 90 95 Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 172 <211> 106 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 172 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 35 40 45 Gln Asp Thr Lys Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg Gln Leu Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 173 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 173 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Gly Gly Asp Asn Ile Gly Thr Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 35 40 45 Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly 85 90 95 Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 174 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 174 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Arg Asn Asn Ile Gly Ser Lys Ser Met 20 25 30 His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 35 40 45 Asp Asn Asn Lys Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu 85 90 95 Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 175 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 175 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Asp Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Tyr Asp Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Ser Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 176 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 176 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Ser His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Tyr Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 177 <211> 110 <212> PRT <213> Synthetic sequence <220> <223> VL <400> 177 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Ala Val Thr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asp Asn His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Asp Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 178 <211> 110 <212> PRT <213> Synthetic sequence <220> <223> VL <400> 178 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asp Asn His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu 85 90 95 Asn Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 179 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 179 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asp Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 180 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 180 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Phe Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Ser Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 181 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> VL <400> 181 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Ala Val Thr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asp Asn His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Asp Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 182 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 182 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asp Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Tyr Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 183 <211> 806 <212> PRT <213> Artificial Sequence <220> <223> FGFR3 <400> 183 Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile 1 5 10 15 Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val 20 25 30 Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln 35 40 45 Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro 50 55 60 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly 65 70 75 80 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val 85 90 95 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg 100 105 110 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala 115 120 125 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr 130 135 140 Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp 145 150 155 160 Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys 165 170 175 Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly 180 185 190 Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly Ile Lys Leu Arg His 195 200 205 Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly 210 215 220 Asn Tyr Thr Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr 225 230 235 240 Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln 245 250 255 Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu 260 265 270 Phe His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu 275 280 285 Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro 290 295 300 Tyr Val Thr Val Leu Lys Thr Ala Gly Ala Asn Thr Thr Asp Lys Glu 305 310 315 320 Leu Glu Val Leu Ser Leu His Asn Val Thr Phe Glu Asp Ala Gly Glu 325 330 335 Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Phe Ser His His Ser Ala 340 345 350 Trp Leu Val Val Leu Pro Ala Glu Glu Glu Leu Val Glu Ala Asp Glu 355 360 365 Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly Phe Phe 370 375 380 Leu Phe Ile Leu Val Val Ala Ala Val Thr Leu Cys Arg Leu Arg Ser 385 390 395 400 Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile Ser Arg 405 410 415 Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser 420 425 430 Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly 435 440 445 Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro Ala Asp Pro Lys 450 455 460 Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu 465 470 475 480 Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile Asp Lys 485 490 495 Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys Met Leu Lys Asp 500 505 510 Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met 515 520 525 Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala 530 535 540 Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Val Glu Tyr Ala Ala Lys 545 550 555 560 Gly Asn Leu Arg Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp 565 570 575 Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu Glu Gln Leu Thr Phe Lys 580 585 590 Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu 595 600 605 Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu 610 615 620 Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe Gly Leu Ala Arg 625 630 635 640 Asp Val His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu 645 650 655 Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr 660 665 670 His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe 675 680 685 Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe 690 695 700 Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro Ala Asn Cys Thr 705 710 715 720 His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser 725 730 735 Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu 740 745 750 Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser Ala Pro Phe Glu 755 760 765 Gln Tyr Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly 770 775 780 Asp Asp Ser Val Phe Ala His Asp Leu Leu Pro Pro Ala Pro Pro Ser 785 790 795 800 Ser Gly Gly Ser Arg Thr 805 <210> 184 <211> 138 <212> PRT <213> Artificial Sequence <220> <223> FGFR3 D1 <400> 184 Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile 1 5 10 15 Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val 20 25 30 Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln 35 40 45 Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro 50 55 60 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly 65 70 75 80 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val 85 90 95 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg 100 105 110 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala 115 120 125 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu 130 135 <210> 185 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Linker <400> 185 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 <210> 186 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> VH CDR3 <400> 186 Asp Tyr Pro Thr Asn Glu Met Ser Arg Phe Asp Tyr 1 5 10 <210> 187 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 187 Asp Gly Pro Thr Asn Glu Met Ser Arg Phe Asp Tyr 1 5 10 <210> 188 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 188 Asp Ala Pro Met Asn Glu Met Ser Arg Phe Asp Tyr 1 5 10 <210> 189 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 189 Asp Ala Pro Thr Asn Glu Ile Ser Arg Phe Asp Tyr 1 5 10 <210> 190 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 190 Asp Ala Pro Thr Asn Glu Pro Ser Arg Phe Asp Tyr 1 5 10 <210> 191 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 191 Asp Ala Pro Thr Asn Glu Glu Ser Arg Phe Asp Tyr 1 5 10 <210> 192 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 192 Asp Gly Pro Met Asn Glu Met Ser Arg Phe Asp Tyr 1 5 10 <210> 193 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 193 Asp Gly Pro Thr Asn Glu Ile Ser Arg Phe Asp Tyr 1 5 10 <210> 194 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 194 Asp Gly Pro Thr Asn Glu Glu Ser Arg Phe Asp Tyr 1 5 10 <210> 195 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 195 Asp Ala Pro Met Asn Glu Ile Ser Arg Phe Asp Tyr 1 5 10 <210> 196 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 196 Asp Ala Pro Met Asn Glu Glu Ser Arg Phe Asp Tyr 1 5 10 <210> 197 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 197 Asp Gly Pro Met Asn Glu Ile Ser Arg Phe Asp Tyr 1 5 10 <210> 198 <211> 12 <212> PRT <213> Artificial sequence <220> <223> VH CDR3 <400> 198 Asp Gly Pro Met Asn Glu Glu Ser Arg Phe Asp Tyr 1 5 10 <210> 199 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 199 Ala Val Trp Asp Tyr Ser Leu Ser Gly Tyr Val 1 5 10 <210> 200 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 200 Ala Ser Trp Asp Tyr Ser Leu Thr Gly Tyr Val 1 5 10 <210> 201 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 201 Ala Ser Trp Asp Tyr Ser Leu Asp Gly Tyr Val 1 5 10 <210> 202 <211> 11 <212> PRT <213> Artificial sequence <220> <223> VL CDR3 <400> 202 Ala Ser Trp Asp Tyr Ser Leu Glu Gly Tyr Val 1 5 10 <210> 203 <211> 121 <212> PRT <213> Artificial sequence <220> <223> VH <400> 203 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Tyr Pro Thr Asn Glu Met Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 204 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 204 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Pro Thr Asn Glu Met Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 205 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 205 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Met Asn Glu Met Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 206 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 206 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Thr Asn Glu Ile Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 207 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 207 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Thr Asn Glu Pro Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 208 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 208 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Thr Asn Glu Glu Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 209 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 209 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Pro Met Asn Glu Met Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 210 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 210 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Pro Thr Asn Glu Ile Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 211 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 211 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Pro Thr Asn Glu Glu Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 212 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 212 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Met Asn Glu Ile Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 213 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 213 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Ala Pro Met Asn Glu Glu Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 214 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 214 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Pro Met Asn Glu Ile Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 215 <211> 121 <212> PRT <213> artificial sequence <220> <223> VH <400> 215 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Tyr Ser Gly Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Pro Met Asn Glu Glu Ser Arg Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 216 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 216 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asp Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp Asp Tyr Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 217 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 217 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asp Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Tyr Ser Leu 85 90 95 Thr Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 218 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 218 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asp Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Tyr Ser Leu 85 90 95 Asp Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 219 <211> 110 <212> PRT <213> artificial sequence <220> <223> VL <400> 219 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ala Asp Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Tyr Ser Leu 85 90 95 Glu Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110
Claims
1. An antibody or antigen-binding fragment thereof that specifically binds to fibroblast growth factor receptor 3 (FGFR3), having a CDR combination selected from the following: (1) heavy chain CDR1 of SEQ ID NO.2, heavy chain CDR2 of SEQ ID NO.20, heavy chain CDR3 of SEQ ID NO.43, light chain CDR1 of SEQ ID NO.68, light chain CDR2 of SEQ ID NO.90, light chain CDR3 of SEQ ID NO.111; (2) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.46, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (3) heavy chain CDR1 of SEQ ID NO.4, heavy chain CDR2 of SEQ ID NO.24, heavy chain CDR3 of SEQ ID NO.47, light chain CDR1 of SEQ ID NO.72, light chain CDR2 of SEQ ID NO.94, light chain CDR3 of SEQ ID NO.115; (4) heavy chain CDR1 of SEQ ID NO.6, heavy chain CDR2 of SEQ ID NO.25, heavy chain CDR3 of SEQ ID NO.48, light chain CDR1 of SEQ ID NO.73, light chain CDR2 of SEQ ID NO.95, light chain CDR3 of SEQ ID NO.112; (5) heavy chain CDR1 of SEQ ID NO.9, heavy chain CDR2 of SEQ ID NO.28, heavy chain CDR3 of SEQ ID NO.51, and light chain CDR1 of SEQ ID NO.76, light chain CDR2 of SEQ ID NO.98, and light chain CDR3 of SEQ ID NO.118; (6) heavy chain CDR1 of SEQ ID NO.10, heavy chain CDR2 of SEQ ID NO.29, heavy chain CDR3 of SEQ ID NO.52, light chain CDR1 of SEQ ID NO.77, light chain CDR2 of SEQ ID NO.97, light chain CDR3 of SEQ ID NO.119; (7) heavy chain CDR1 of SEQ ID NO.11, heavy chain CDR2 of SEQ ID NO.30, heavy chain CDR3 of SEQ ID NO.53, light chain CDR1 of SEQ ID NO.78, light chain CDR2 of SEQ ID NO.99, light chain CDR3 of SEQ ID NO.120; (8) heavy chain CDR1 of SEQ ID NO.11, heavy chain CDR2 of SEQ ID NO.31, heavy chain CDR3 of SEQ ID NO.54, light chain CDR1 of SEQ ID NO.79, light chain CDR2 of SEQ ID NO.100, light chain CDR3 of SEQ ID NO.121; (9) heavy chain CDR1 of SEQ ID NO.12, heavy chain CDR2 of SEQ ID NO.32, heavy chain CDR3 of SEQ ID NO.55, light chain CDR1 of SEQ ID NO.80, light chain CDR2 of SEQ ID NO.101, light chain CDR3 of SEQ ID NO.122; (10) heavy chain CDR1 of SEQ ID NO.3, heavy chain CDR2 of SEQ ID NO.33, heavy chain CDR3 of SEQ ID NO.56, light chain CDR1 of SEQ ID NO.81, light chain CDR2 of SEQ ID NO.102, light chain CDR3 of SEQ ID NO.123; (11) heavy chain CDR1 of SEQ ID NO.13, heavy chain CDR2 of SEQ ID NO.34, heavy chain CDR3 of SEQ ID NO.57, light chain CDR1 of SEQ ID NO.82, light chain CDR2 of SEQ ID NO.103, light chain CDR3 of SEQ ID NO.124; (12) heavy chain CDR1 of SEQ ID NO.14, heavy chain CDR2 of SEQ ID NO.35, heavy chain CDR3 of SEQ ID NO.58, light chain CDR1 of SEQ ID NO.83, light chain CDR2 of SEQ ID NO.104, light chain CDR3 of SEQ ID NO.125; (13) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.187, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (14) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.188, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (15) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.189, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (16) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.191, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (17) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.192, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (18) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.193, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (19) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.195, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (20) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.197, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (21) heavy chain CDR1 of SEQ ID NO.5, heavy chain CDR2 of SEQ ID NO.23, heavy chain CDR3 of SEQ ID NO.198, light chain CDR1 of SEQ ID NO.71, light chain CDR2 of SEQ ID NO.93, light chain CDR3 of SEQ ID NO.114; (22) the heavy chain CDR1 of SEQ ID NO.5, the heavy chain CDR2 of SEQ ID NO.23, the heavy chain CDR3 of SEQ ID NO.46, and the light chain CDR1 of SEQ ID NO.71, the light chain CDR2 of SEQ ID NO.93, and the light chain CDR3 of SEQ ID NO.201; and (23) The heavy chain CDR1 of SEQ ID NO.5, the heavy chain CDR2 of SEQ ID NO.23, the heavy chain CDR3 of SEQ ID NO.46, and the light chain CDR1 of SEQ ID NO.71, the light chain CDR2 of SEQ ID NO.93, and the light chain CDR3 of SEQ ID NO.
202.
2. The antibody or antigen-binding fragment thereof according to claim 1, which has a combination of heavy chain variable region and light chain variable region selected from the following: (1) the heavy chain variable region of SEQ ID NO.134 and the light chain variable region of SEQ ID NO.159; (2) the heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.162; (3) the heavy chain variable region of SEQ ID NO.138 and the light chain variable region of SEQ ID NO.163; (4) the heavy chain variable region of SEQ ID NO.139 and the light chain variable region of SEQ ID NO.164; (5) the heavy chain variable region of SEQ ID NO.142 and the light chain variable region of SEQ ID NO.167; (6) the heavy chain variable region of SEQ ID NO.143 and the light chain variable region of SEQ ID NO.168; (7) the heavy chain variable region of SEQ ID NO.144 and the light chain variable region of SEQ ID NO.169; (8) the heavy chain variable region of SEQ ID NO.145 and the light chain variable region of SEQ ID NO.170; (9) the heavy chain variable region of SEQ ID NO.146 and the light chain variable region of SEQ ID NO.171; (10) the heavy chain variable region of SEQ ID NO.147 and the light chain variable region of SEQ ID NO.172; (11) the heavy chain variable region of SEQ ID NO.148 and the light chain variable region of SEQ ID NO.173; (12) the heavy chain variable region of SEQ ID NO.149 and the light chain variable region of SEQ ID NO.174; (13) the heavy chain variable region of SEQ ID NO.204 and the light chain variable region of SEQ ID NO.162; (14) the heavy chain variable region of SEQ ID NO.205 and the light chain variable region of SEQ ID NO.162; (15) the heavy chain variable region of SEQ ID NO.206 and the light chain variable region of SEQ ID NO.162; (16) the heavy chain variable region of SEQ ID NO.208 and the light chain variable region of SEQ ID NO.162; (17) the heavy chain variable region of SEQ ID NO.209 and the light chain variable region of SEQ ID NO.162; (18) the heavy chain variable region of SEQ ID NO.210 and the light chain variable region of SEQ ID NO.162; (19) the heavy chain variable region of SEQ ID NO.212 and the light chain variable region of SEQ ID NO.162; (20) the heavy chain variable region of SEQ ID NO.214 and the light chain variable region of SEQ ID NO.162; (21) the heavy chain variable region of SEQ ID NO.215 and the light chain variable region of SEQ ID NO.162; (22) the heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.218; and (23) The heavy chain variable region of SEQ ID NO.137 and the light chain variable region of SEQ ID NO.
219. 3 . The antibody or antigen-binding fragment thereof according to claim 1 , comprising a single-chain antibody, Fab, F(ab′), or a disulfide-linked Fv (sdFv). The antibody or antigen-binding fragment thereof according to claim 3 , wherein the single-chain antibody is a single-chain Fv (scFv).
5. The antibody or antigen-binding fragment thereof according to claim 4, characterized in that: The scFv is formed by connecting the heavy chain variable region and the light chain variable region via a linker.
6. The antibody or antigen-binding fragment thereof according to claim 5, wherein The linker comprises (G n S) m , where n and m are 1 to 10 respectively. 7 . A nucleic acid encoding the antibody or antigen-binding fragment thereof according to claim 1 . A recombinant expression vector comprising the nucleic acid of claim 7 .
9. A host cell transfected with the recombinant expression vector according to claim 8.
10. The host cell according to claim 9, wherein The host cell is CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S or HT1080.
11. A method for preparing an antibody or an antigen-binding fragment thereof that specifically binds to FGFR3, comprising the following steps: Cultivating the host cell of claim 9 to form antibodies; as well as The antibodies formed are isolated and purified. 12 . A bispecific antibody or a multispecific antibody comprising the antibody or antigen-binding fragment thereof according to claim 1 .
13. The bispecific antibody or multispecific antibody according to claim 12, wherein: The bispecific antibody or multispecific antibody comprises one or more selected from PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO as a partner.
14. An immune cell engaging bispecific antibody or multispecific antibody comprising an scFv of the antibody of any one of claims 1 to 6 and an scFv consisting of a second binding domain, wherein the second binding domain comprises one or more scFvs of antibodies that bind to an immune cell activating antigen.
15. The bispecific antibody or multispecific antibody according to claim 14, wherein: The scFv is formed by connecting the heavy chain variable region and the light chain variable region via a linker.
16. The bispecific antibody or multispecific antibody according to claim 15, wherein: The linker comprises (G n S) m , where n and m are 1 to 10 respectively.
17. An antibody-drug conjugate (ADC), which is formed by combining the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 with a drug.
18. The antibody-drug conjugate according to claim 17, characterized in that: The drugs are: (1) an anticancer agent selected from the group consisting of maytansine compounds, auristatins, aminopterin, actinomycin, bleomycin, talithromycin, camptothecin, N8-acetyl spermidine, 1-(2-chloroethyl)-1,2-dimethylsulfonyl hydrazide, esperamicin, etoposide, 6-mercaptopurine, dolestacin, trichothecenes, calicheamicin, taxol, taxane, paclitaxel, docetaxel, methotrexate, vincristine, vinblastine, doxorubicin, melphalan, chlorambucil, duocarbinase, L-asparaginase, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, methyl benzylhydrazine, topotecan, nitrogen mustard, cyclophosphamide, etoposide, 5-fluorouracil, dichloroethyl nitrosourea, irinotecan, camptothecin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinorelbine, chlorambucil, melphalan, carmustine, lomustine, busulfan, trioxalic acid, dacarbazine, etoposide, teniposide, topotecan, 9-aminocamptothecin, clenatol, trimetrexate, mycophenolic acid, thiazofuran, ribavirin, 5-ethynyl-1-β-D-ribofuranosyl imidazole-4-carboxamide, hydroxyurea sulfate, deferoxamine, floxuridine, doxifluridine, raltitrexed, cytarabine (arabinoside) C), one or more of cytosine arabinoside, fludarabine, tamoxifen, raloxifene, megestrol acetate, goserelin, leuprolide acetate, flutamide, bicalutamide, EB1089, CB1093, KH1060, verteporfin, phthalocyanine, photosensitizer Pe4, demethoxy-hypocrellin A, interferon-α, interferon-γ, tumor necrosis factor, gemcitabine, velcade, remide, tyramide, lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, actinomycin D, dactinomycin, pelocycin, epirubicin, pirarubicin, doxyrubicin, mitoxantrone, verapamil, thapsigargin and nuclease; (2) anti-inflammatory drugs, including steroid preparations, nonsteroidal anti-inflammatory drugs (NSAIDs) or immunospecific anti-inflammatory drugs (ImSAIDs); or (3) An agent for treating immune diseases, which comprises chlorambucil, cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine or methotrexate.
19. The antibody-drug conjugate according to claim 18, wherein the mitomycin is selected from mitomycin A and mitomycin C, and the bleomycin is selected from bleomycin A2 and bleomycin B2.
20. The antibody-drug conjugate according to claim 17, wherein the drug is a toxin derived from bacteria, animals or plants.
21. The antibody-drug conjugate according to claim 17, characterized in that: The antibody or antigen-binding fragment thereof is bound to the drug via a linker.
22. The antibody-drug conjugate according to claim 21, characterized in that The linker is a cleavable linker or a non-cleavable linker.
23. The antibody-drug conjugate according to claim 22, characterized in that: The cleavable linker is an acid-labile linker, a disulfide linker, a peptide linker or a β-glucuronide linker, or the non-cleavable linker comprises a thioether group or a maleimidocaproyl group.
24. The antibody-drug conjugate according to claim 21, characterized in that: The linker binds to a cysteine residue exposed upon reduction of disulfide bonds of the antibody or to a cysteine residue present on a tag bound to the antibody.
25. A chimeric antigen receptor, characterized in that The chimeric antigen receptor (CAR) comprises: an extracellular domain comprising an antigen binding site, a transmembrane domain and an intracellular signaling domain, wherein the antigen binding site of the extracellular domain is the scFv of the antibody of any one of claims 1 to 6.
26. The chimeric antigen receptor according to claim 25, characterized in that The scFv is formed by connecting the heavy chain variable region and the light chain variable region via a linker.
27. The chimeric antigen receptor according to claim 26, wherein The linker comprises (G n S) m , where n and m are 1 to 10 respectively.
28. An immune cell, wherein: The chimeric antigen receptor (CAR) according to claim 25 is introduced into the immune cell.
29. The immune cell according to claim 28, wherein The immune cells are selected from one or more of T cells, NK cells, macrophages, and dendritic cells.
30. The immune cell according to claim 28, wherein The immune cells are selected from the group consisting of activated cytotoxic T lymphocytes, tumor infiltrating T cells and cytokine-induced killer cells.
31. The immune cell according to claim 28, wherein A chimeric antigen receptor (CAR) comprising an antigen binding site for an scFv of an antibody other than the anti-FGFR3 antibody as an extracellular domain is further introduced into the immune cell.
32. The immune cell according to claim 31, wherein The antibody other than the anti-FGFR3 antibody is an antibody targeting one or more selected from the following: PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
33. A combination therapy composition comprising the immune cell of claim 28 and a drug other than an anti-FGFR3 antibody.
34. The composition according to claim 33, wherein The drug other than the anti-FGFR3 antibody is an antibody targeting one or more selected from the following: PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
35. A combination therapy composition comprising an antibody or antigen-binding fragment thereof as described in any one of claims 1 to 6, and one or more selected from (i) immune cells; (ii) immune cells comprising a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises an scFv fragment of an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) immune checkpoint inhibitors.
36. The composition according to claim 35, wherein The immune cells are one or more selected from T cells, NK cells, macrophages and dendritic cells.
37. The composition according to claim 35, wherein The immune cells are selected from the group consisting of activated cytotoxic T lymphocytes, tumor infiltrating T cells and cytokine-induced killer cells.
38. The composition according to claim 35, wherein The antibody other than the anti-FGFR3 antibody is an antibody targeting one or more selected from the following: PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
39. The composition according to claim 35, wherein The immune checkpoint inhibitor targets one or more drugs selected from PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
40. A combination therapy composition comprising the bispecific antibody or multispecific antibody of claim 12, and one or more selected from (i) immune cells; (ii) immune cells comprising a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises an scFv fragment of an antibody other than an anti-FGFR3 antibody as an extracellular domain; and (iii) immune checkpoint inhibitors.
41. The composition according to claim 40, wherein The antibody other than the anti-FGFR3 antibody is an antibody targeting one or more selected from the following: PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
42. The composition according to claim 40, wherein The immune checkpoint inhibitor targets one or more drugs selected from PD-1, PD-L1, BTLA, CTLA-4, LAG3, TIM3, CD137 (4-1BB), VISTA, CD258 (LIGHT), TIGIT, CD134 (OX40), CD28, CD278 (ICOS), CD27, CD154 (CD40L), CD357 (GITR), CD30, DR3, CD226 (DNAM1), CD96, CD200, CD200R, transferrin receptor, c-Met, EGFR, HER2, KDR, PDGFRa, NRP1, and MARCO.
43. A composition for treating cancer, inflammation or immune disease, comprising: the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, a bispecific antibody or a multispecific antibody comprising the antibody or antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof, a chimeric antigen receptor comprising the antibody or antigen-binding fragment thereof, or an immune cell comprising the chimeric antigen receptor.
44. A composition for treating cancer, inflammation or immune disease, comprising: the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, or an antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof.
45. A composition for treating cancer, inflammation or immune disease, which is used to treat cancer, inflammation or immune disease confirmed to be amplified, mutated, overexpressed or always expressed fusion gene of FGFR3 and TACC3, and the composition comprises: the antibody or its antigen-binding fragment described in any one of claims 1 to 6, a bispecific antibody or multispecific antibody comprising the antibody or its antigen-binding fragment, an antibody-drug conjugate comprising the antibody or its antigen-binding fragment, a chimeric antigen receptor comprising the antibody or its antigen-binding fragment, or an immune cell comprising the chimeric antigen receptor.
46. Use of the antibody or its antigen binding fragment described in any one of claims 1 to 6, a bispecific antibody or a multispecific antibody comprising the antibody or its antigen binding fragment, an antibody-drug conjugate comprising the antibody or its antigen binding fragment, a chimeric antigen receptor comprising the antibody or its antigen binding fragment, or an immune cell comprising the chimeric antigen receptor in the preparation of a medicament for treating a patient's cancer, inflammation or immune disease, wherein amplification of the fusion gene of FGFR3 and TACC3, variation in the fusion gene, overexpression of the fusion gene, or constant expression of the fusion gene is confirmed in a sample derived from the patient.
47. A vesicle, wherein: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 is exposed on the outside of the vesicle or exists inside the vesicle.
48. The vesicle of claim 47, wherein The vesicles are exosomes.
